C. Scully, CBE, London, UK
Professor Crispian Scully CBE, MD, PhD, MDS, MRCS, BSc, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA,
FUCL, DSc, DChD, DMed(HC)
Crispian Scully is Director of Special Projects at the UCL-Eastman Dental Institute (EDI); Professor of
Special Care Dentistry, University College London; Chairman of International Federation of Oral Medicine; Past-President of European
Association of Oral Medicine; President-elect of International Academy of Oral Oncology, member of the Hellenic Quality Assurance Agency
for Higher Education and member of International Committee of the American Academy for Oral Medicine and Royal College of Surgeons Edinburgh
Dental Council. Co-director of the World Health Organisation Collaborating Centre for oral health, disability and culture, he is also
a member of UK Academy of Medical Sciences, a member of National Centre for Health and Clinical Excellence (NICE) working group on Oral
Cancer and advisory subcommittee on CJD, a member of Higher Education Funding Council (HEFCE) Dental Research Review Panel, a member
of Court of Middlesex University, a Trustee of Mouth Cancer Foundation, and member of Oral Cancer Foundation; Science Advisory Board.
He has been for some years, Visiting Professor at the Universities of Bath, Edinburgh, Helsinki, Hertfordshire, Middlesex and West of
England.
He was Dean at the University of Bristol for 5 years, and Dean at EDI 1993-2008, gaining the Queen's Award for Higher and
Further Education in 2002/2003 - the first in dentistry. He has written 30 and edited 11 books and over 800 papers cited on MEDLINE;
his book Medical Problems in Dentistry was awarded the Doody Prize as one of the top-selling medical or dental books worldwide,
his Atlas has BMA High Commendation and Oral and Maxillofacial Medicine won the Society of Authors Prize and also BMA High Commendation
for the second edition.
He is Editor of Oral Oncology, and Oral Diseases, and Associate Editor of Journal of
Investigative and Clinical Dentistry. He has received the CBE, University of Helsinki Medal of Honour, University of Santiago de
Compostela Medal, University of Granada Medal, Fellowship of UCL, honorary degrees from Universities of Athens, Granada, Helsinki and
Pretoria, Dental Awards for the Most Outstanding Achievements in Dentistry and American Biographical Institute UK Man of the Year.
• Graduate in Medicine and Surgery. Valencia University Faculty of Medicine (Spain), June 1978.
• Specialist in Stomatology. School of Stomatology, Valencia University. Faculty of Medicine. 1980. • Doctor in Medicine
(PhD). Valencia University. Faculty of Medicine. With Honors (cum laude). 1984. • Extraordinary Doctorate Prize, Valencia University.
1985. • Full Professor of Oral Medicine. Valencia University. Faculty of Medicine and Odontology. April 20, 1990 to date. • Head, Service of Stomatology, Valencia University General Hospital. January 8, 1993 to date. • Author of seven books
on Oral Medicine. • Author of 33 book chapters, all on Oral Medicine. • Author of 243 published papers in Oral Medicine
• Author of 238 Free communications in Congress. • Director of 36 Doctoral Theses • Awarded 17 Prizes in
Odontostomatology. • President of the Research Commission, Valencia University General Hospital. • Director of the
journal, Medicina Oral, Patologia Oral y Cirugia Bucal
L. Kowalski, BrazilProfessor Luiz Paulo Kowalski graduated from the Medical School of the Universidade Federal do Paraná, Curitiba, Brazil (1979).
After a 3 year residency in Surgical Oncology at Hospital do Cancer A C Camargo in São Paulo, he undertake a one-year Fellowship
in Head and Neck Surgery at Hospital Heliópolis. He obtained his MS degree (1986) and PhD degree (1989) in Otorhinolaryngology
from the Escola Paulista de Medicina in São Paulo. During his Post-Graduation he also completed a 6-months observership in Head
and Neck Surgery at Memorial Sloan-Kettering Cancer Center (1988). In 1996 he obtained the academic title of Free-Professor of Oncology
at Universidade de São Paulo.
In 1990, he was recruited to the Hospital do Cancer A C Camargo as the Director of the Department
of Head and Neck Surgery and Otorhinolaryngology. Academic appointments for Dr. Kowalski have included Professor of the Postgraduate
Course of Oncology at University of São Paulo (since 1991) and Professor of the Postgraduate Course of Oncology at Fundação
Antonio Prudente (since 1997).
Dr Kowalski has undertaken research mainly into epidemiology, prognostic factors, oral cancer, larynx
cancer, base of the skull malignant tumors, management of the neck and biomarkers.He has authored or co-authored more than 150 peer reviewed
articles (58 in international journals), written 3 theses and 51 book chapters, and edited 5 books which included the Brazilian translation
of the 2nd edition of Dr Jatin Shah's book, Head and Neck Surgery.
He is a member of several professional organizations, including
the American Head and Neck Society, Brazilian Head and Neck Surgery Society, Brazilian Otorhinolaryngology Society, Brazilian Base of
the Skull Society, Brazilian College of Surgeons, and is a Past President of the Head and Neck Surgery Department of the São Paulo
Medical Association. He served as Scientific Director of the Brazilian Head and Neck Cancer Society, President of the IV Brazilian Oral
Cancer Congress, Chairman of several multi-institutional studies, and was an active participant of the program committee for several
Brazilian and International meetings.
C. La Vecchia, Italy
Date of birth: Feb. 27, 1955; Place of birth: Milano, Italy; Citizienship: Italian; Languages: English,
French (and Italian). Current status: Head, Laboratory of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri",
Milan (Italy). Associate Professor of Epidemiology, Istituto di Statistica Medica e Biometria, Universita di Milano. Adjunct
Professor of Epidemiology, University of Lausanne, Switzerland. Adjunct Professor of Medicine, School of Medicine, Vanderbilt University,
Nashville, TN .
Address: Istituto di Ricerche Farmacologiche"Mario Negri" Via Eritrea 62 - 20157 Milan (Italy) Tel.
+39-02-39014.1; Fax +39-02-33200231/02-39001916 Istituto di Statistica Medica e Biometria, Universita di Milano, Via Venezian 1 -
20133 Milan (Italy) Tel.+39-02-2361302; Fax +39-02-2362930.
Work and related experience: o 1979 March to date - Researcher
at the Istituto di Ricerche Farmacologiche "Mario Negri", Milan. o 1981-1983 -Research Fellow at the Dept. of Community Medicine
and Medical Practice, Univ. of Oxford. o from 1987 to 1992 - Associate Professor of Epidemiology, University of Lausanne. o from
Jan. 1989 - Head, Laboratory of Epidemiology, Istituto di Ricerche Farmacologiche "M.Negri". o 1992 from November - Associate Professor
of Epidemiology, University of Milan. o from 1996 to 2001 - Adjunct Associate Professor of Epidemiology, Harvard School of Public
Health, Boston, MA
Awards: o 1979-1982 - Three-year Scholarship from Regione Lombardia for Medical Research o 1981-1983
- Two-year Research Training Fellowship by the Italian Labor Ministry and the EEC o 1991 - European Visiting Professor to the Royal
Society of Medicine, London. o 1993 - Glaxo Prize for medical publications.
Miscellanea: o Registered Journalist, Milan
(Elenco pubblicisti No. 52412). o Honorary Senior Lecturer in Oral Medicine, Eastman Dental Institute, University College London
(1996-2001). o Visiting Lecturer in the Department of Epidemiology, Harvard School of Public Health, Boston, Mass., U.S.A. (1994-1995). o Member of the UICC - American Cancer Society Fellowship Committee (1991-95). o Member of the "Steering Committee" of the international
cooperative network of case-control of the SEARCH Programme of the International Agency for Research on Cancer, IARC/OMS (1989-91). o
Temporary advisor at the International Agency for Research on Cancer, IARC/WHO and at the WHO, Geneva (1989--). o Member of the Executive
Committee of the European Society for Human Reproduction (ESHRE) (1991-95). o Member of the Steering Committee, Collaborative Group
on Hormonal Factors and Breast Cancer, Oxford, UK. o Member of the Scientific Committee, Air Quality Project, Fondazione Lombardia
Ambiente, Regione Lombardia (1998-2000). o Member of the CPMP Ad hoc Expert Group on Oral Contraceptives and Cardiovascular Risks,
EMEA, London, 1998-2001. o Consultant, U.S. Surgeon General's Report on Smoking and Women's Health (1997-2000). o Member, Scientific
Board of the Italian Group of Epidemiologic Studies in Dermatology (GISED, 2001--). o President, Societa Italiana della Riproduzione
(2002-2003). o Member of the Board of Trustees, International Health Foundation, Utrecht (2001-2004).
Editor: European
Journal of Public Health (1993--) - Journal of Epidemiology and Biostatistics (1996--)
Member of the Editorial board of the following
journals: American J. of Epidemiology (1991-97) - Asian Pacific J. of Cancer Prevention (2000--) - Cancer Causes and Control
(1991-96) - Digestive and Liver Disease (2001--) - European J. of Cancer (1991-95) - European J. of Cancer Prevention (1991--) - European
J. of Clinical Nutrition (1996) - Int. J. Cancer (2000--) - J. of Nephrology (1992--) - Nutr. Cancer (2000--) - Oncology (1994-95) -
Revisiones en Ginecologia y Obstetricia (2000--) - Revista Española de Nutricion Comunitaria (1996--)- Revue d'Epidemiologie et
de Sante Publique (1991--) - Sozial und Praeventivmedizin (1990--2001) -Tumori (1993--)- Alimentazione e Prevenzione (2000--).
J. Lefebvre, FranceProfessor Jean-Louis LeFebvre received his medical training in Lille University (1963 - 1970) and in the ENT and Head and Neck Surgery
Service of the University Hospital (1970 - 1974). He upheld his thesis on "Supracricoid Laryngectomies" in 1974. During his residency
he focused his activities on head and neck cancer. He was appointed senior resident both in the ENT and Head and Neck Surgery Service
and in Anatomy and Organogenesis (1974 -1976).
In 1976, he was appointed Chief of Head and Neck Outpatient Clinic, in the Head and
Neck Department of Centre Oscar Lambret, the Northern France Comprehensive Cancer Center. He became Chief of the Department in 1994 and
took, in addition, the position of Deputy Director of the Cancer Center in 1996 to 2001.
He chaired the Head and Neck Group of the
European Organization for Research and Treatment of Cancer (EORTC: 1989 - 1998) and was a member of the EORTC Board from 1997 to 1999.
He is member of 18 Head and Neck societies. In 1995 he was awarded the Special Recognition Award of the Society of Head and Neck Surgeons.
He gave in 1996 the Myers International Lecture at the American Academy and in 1999 the Hayes Martin Lecture at the American Head and
Neck Society.
He has published 258 papers, abstracts and chapters, directed 52 theses in medicine and has lectured extensively (199)
throughout the world mainly on the topics of larynx surgery, organ preservation and clinical research.
J. Sciubba, USA
Dr. Sciubba is recently retired from the Johns Hopkins School of Medicine where he served as a full Professor
in the Departments of Otolaryngology-Head and Neck Surgery, Pathology and Dermatology. Currently he is in part time private practice
in the Baltimore community and is an active consultant at The M.J. Dance Head and Neck Cancer Center at The Greater Baltimore Medical
Center.
Dr. Sciubba has extensive experience in the diagnosis and management of a wide scope of oral, jawbone and salivary diseases.
He remains active as an Editor, associate editor and reviewer of several journals including Oral Oncology, The Compendium of Continuing
Dental education, The Journal of Dental Research / Critical Reviews in Oral Biology and Medicine and Grand Rounds in Oral and Systemic
Medicine. Most recently he was appointed as a Senior Advisor to the Editorial Board of Oral Oncology, the leading journal of its type
in the world. He is an active reviewer for many journals, some of which include Oral Oncology, JADA, Oral Diseases, Head and Neck, Archives
of Otolaryngology, The Laryngoscope, The International Journal of Oral and Maxillofacial Surgery and The Journal of Oral and Maxillofacial
Surgery. He has served as the Oral Pathology editor of "Triple O" for six years, as was Associate Editor of The Journal of Oral Pathology
and Medicine for 13 years. He has authored or coauthored as well as edited, several books, and over 200 peer reviewed papers, abstracts
and chapters, and has lectured extensively throughout the US, Canada, Europe, Central and South America and Asia.
J. Shah, USAProfessor Jatin P. Shah graduated from the Medical College of MS University in Baroda, India. He completed his post-graduate training
in general surgery at that institution, receiving the degree of Master of Surgery. He then came to the United States for further training
in surgery, surgical oncology, and head and neck surgery. Upon completion of his surgical training in Philadelphia and New York, he
joined the full time faculty of Memorial Sloan-Kettering Cancer Center in New York.
Professor Shah is a national and international
leader in the field of head and neck surgery, having served as President of the New York Cancer Society, New York Head and Neck Society,
and the Society of Head and Neck Surgeons. He also serves as the Secretary-General of the International Federation of Head and Neck
Oncologic Societies since its inception and was elected by both the Society of Head and Neck Surgeons and the American Society for Head
and Neck Surgery as Conference Chairman for the Fourth International Conference on Head and Neck Cancer in Toronto in 1996. He served
the Joint Training Council of the American Head and Neck Society as its secretary and chairman. He has served in varying capacities
for the American Board of Surgery, The American College of Surgeons, and the American Joint Committee for Cancer Staging (AJCC) as Chairman
of its Head and Neck Sites.
Professor Shah has been the recipient of numerous awards from various parts of the world and has been
elected as an honorary member of several head and neck societies in Europe, Asia, Australia, Africa and Latin America. He had been listed
in the "Best Doctors in America" directories for several years. He serves on the Editorial and Review Boards of 18 scientific journals
and has published over 216 peer-reviewed publications 50 book chapters and 6 books. The Second Edition of his book, Head and Neck Surgery,
won the First Prize from the British Medical Association as the best surgical book for 1997 and the book was also Winner of the Best
Surgical Atlas Prize from The Royal Society of Medicine.
His areas of clinical interest are in the field of skull base surgery,
reconstructive surgery, and conservation surgery of larynx as well as multidisciplinary treatment programs in organ and function preservation.
His areas of basic research include chemoprevention and in vitro drug response assays for predicting chemosensitivity of malignant tumors
of the head and neck.
He is a much sought after speaker who has delivered over 600 scientific presentations including keynote addresses,
named lectureships, and visiting professorships in the United States, Australia, United Kingdom, Canada, South Africa, Sweden, Scotland,
and numerous countries in Latin America and Asia. He was the recipient of the Royal Society of Medicine Visiting Professorship for 1997.
He is Director of an Advanced Fellowship Program in Head and Neck Surgery and Oncology at Memorial Sloan-Kettering Cancer Center which
has attracted some of the best trainees from the United States and abroad. The graduates of his program have uniformly pursued academic
careers in the United States and various parts of the world.
He is currently Program Director, Chief of the Head and Neck Service,
and Professor of Surgery and holds the Elliot W. Strong Chair in Head and Neck Oncology at Memorial Sloan-Kettering Cancer Center in
New York City.
Dr. Sidransky received his MD in 1984 from Baylor College of Medicine in Houston, and then completed an
internal Medicine residency at Baylor. In 1988, he pursued a Clinical Oncology fellowship at Hopkins and then completed a research fellowship
under Dr. Bert Vogelstein. He worked in Dr. Vogelstein's laboratory pursuing the genetics of various types of cancer. It was there that
he first discovered that Ras gene mutations could be identified in the stool of patients with colorectal cancer' opening up
a new molecular approach for the detection of human cancer. Dr. Sidransky then joined the Hopkins faculty in 1992 and was promoted to
his current position in 1998.
Dr. Sidransky is currently Professor of Otolaryngology - Head and Neck Surgery, Oncology, Pathology,
Urology, and Cellular and Molecular Medicine, and is Director of Head and Neck Cancer Research Laboratory at The Johns Hopkins University.
His laboratory includes approximately 25 members and is actively engaged in the elucidation of molecular genetic changes that drive the
progression of various types of cancer. He has worked diligently on identifying new genetic changes on smoking associated tumors including
lung cancer, head and neck cancer and bladder cancer. He has also published on the molecular epidemiology of smoking-induced cancers
and the link between tobacco smoke and mutations of critical oncogenes.
Dr. Sidransky's work is best known for his pioneering efforts
in molecular detection approaches based on the identification of clonal genetic changes in many bodily fluids including urine, saliva,
stool, and blood. Several major recent innovations in this area have been pioneered by the Sidransky laboratory. Many of these approaches,
such as the hypermethylation of p16 in human cancers and the discovery of mitochondrial mutations at high frequency in many tumor types
have shed new light in the field of cancer biology and detection. Dr. Sidransky also discovered that circulating free DNA was derived
from tumor cells by showing that this DNA shared the identical genetic changes present in the primary turnor. This approach may one day
lead to a simple blood test can detect cancers at an early stage. Dr. Sidransky has also led investigations in molecular staging based
on the identification of micro metastatic disease in various tumor types. This approach may one day set the standard for staging patients
with cancer and will allow for more aggressive therapy in patients with minimal residual disease. Throughout his career, Dr. Sidransky
has tried to bridge basic research into the clinical setting.
Dr. Sidransky currently serves as Senior or Associate Editor of four
major cancer research journals and is on the board of scientific counsellors for the NIDCR at the NIH. He has published over 200 scholarly
works including over 150 journal articles and many reviews and commentaries. Recent awards include the Sarstedt International Research
Prize (German Society of Clinical Chemistry 1997), The Alton Ochsner Award Relating Smoking and Health (American College of Chest Physicians
1998) and his selection by Time Magazine as America's best in Oncology in 2001.
S. Sonis, USAProfessor Stephen Sonis received his dental degree from Tufts University, Boston, USA in 1972, and then entered a combined doctorate and
clinical specialty-training program at Harvard. Following completion of his doctoral degree in tumor immunology and clinical programs
in Oral Medicine and Periodontology, Professor Sonis was awarded a Knox Fellowship to study at Oxford, UK with Ian MacLennan. In 1977,
he returned to the USA to accept joint positions at the Peter Bent Brigham Hospital, Sidney Farber Cancer Center and the Harvard School
of Dental Medicine and to assume the leadership of the fledgling dental residency program. In 1978, following the consolidation of three
of Harvard's teaching hospitals, Professor Sonis was appointed the divisional Chief. Currently, Professor Sonis is the Chief of the
Division of Oral Medicine, Oral and Maxillofacial Surgery and Dentistry at the Dana-Farber Cancer Institute, Senior Surgeon at Brigham
and Women's Hospital, and Professor and Chair of the Department of Oral Medicine and Diagnostic Sciences at Harvard.
His research
activities initially focused on laboratory investigation of lymphocyte-neutrophil interactions and the initiation of descriptive clinical
studies on the oral complications of cancer therapy. His research latterly has converged to focus on the biology of cancer regimen-related
mucosal toxicities.
Professor Sonis has published extensively on the clinical, biological, and health economic aspects of oral complications
of cancer therapy. He is the author of over 90 original publications, 30 reviews and chapters, 5 books and numerous abstracts. He is
a frequent invited speaker at national and international meetings.
Professor Sonis has served on the editorial boards of numerous
journals and is an associate editor of the Harvard Medical School Family Health guide, a Web book supplement. Professor Sonis is a founding
member of the International Society of Oral Oncology.
P. Speight, UKProfessor Paul M Speight, PhD, BDS, FDSRCPS, FDSRCS (Eng), FDSRCS (Edin.), FRCPath
Paul Speight qualified in Dentistry at the University
of Manchester in 1978, followed by clinical training and research at the University of Dundee. He was Senior Lecturer in Oral Pathology
at the Royal London Hospital Medical College and then from 1994 to 2003 was Professor and Head of the Unit of Oral & Maxillofacial
Pathology at the Eastman Dental Institute and from 2002 was Head of Cellular Pathology at University College London Hospitals NHS Trust.
In September 2003 he moved to the Chair of Oral Pathology at the University of Sheffield. He has a number of national and international
assignments, including Editor-in-Chief of Archives of Oral Biology, President of the International Association of Oral Pathologists and
a Past-President of the British Society for Oral and Maxillofacial Pathology.
He is a diagnostic pathologist with special expertise
in lesions of the jawbones, including odontogenic tumors, and salivary glands. His main research interests are in the field of oral cancer,
including biomarkers and studies to evaluate oral cancer screening. He has published over 150 original research papers as well as a
number of chapters in specialist textbooks.
H. Tanzawa, JapanProfessor Hideki Tanzawa, MD, DDS, PhD. graduated from School of Medicine, Chiba University (1982) and also from School of Dentistry,
Tokyo Medical and Dental University (1986). He trained as an anesthetist, a general surgeon and a head and neck surgeon in Chiba University
Hospital, Narashino National Hospital and Chiba Prefecture Cancer Center (1982-1991). Simultaneously, he started his research work in
Graduate School of Medicine, Chiba University and his Doctor of Medicine was awarded in 1991. He was appointed Lecturer (1991), Assistant
Professor (1994) and then Associate Professor (1995) in Department of Oral Surgery, School of Medicine Chiba University. In 1997, he
was appointed Professor of Oral Science and Head of Oral Surgery at School of Medicine and University Hospital, Chiba University. He
was appointed Chairman and Professor of Department of Clinical Molecular Biology in 2001 and Vice-Dean of Graduate School of Medicine,
Chiba University (2005).
His main research interests in oral cancer have been in oral squamous cell carcinoma. His group showed the
possible associations with human papillomaviruses in Japan. Other studies have shown oncogene and tumour suppressor alterations in oral
squamous cell carcinoma. Out of number of candidates, he was selected as a Leader of big national projects, the 21st Century COE Program,
which was a research and educational program concerning advanced gene therapy and heavy-ion radiotherapy for squamous cell carcinoma
of the digestive organ (2003-2008), and the Educational Program for the Specialist of Cancer Treatment (2007-2012). He was also selected
Chief Researcher of a big project funded by Japan Science and Technology Agency, creating a new technology of the chemotherapy (2007-2011).
Professor Tanzawa and his team are now developing new methods and medicines for the effective radiotherapy and chemotherapy.
I. van der Waal, The Netherlands
Professor Isaac van der Waal graduated from Dental School in 1968 at the University of Utrecht, the Netherlands,
and took a one-year rotating internship at Eastman Dental Center, Rochester, New York. He received his Oral Surgery and Oral Pathology
training at the Vrije Universiteit in Amsterdam, The Netherlands. In 1973 he defended his thesis on "Carcinoma of the Tongue; a clinicopathologic
study". From 1975-1976 he served a Fellowship in Oral Pathology at the Armed Forces Institute of Pathology in Washington D.C. In 1979
he was appointed full Professor in Oral Pathology at the University Hospital Vrije Universiteit. At present, he is head of the Department
of Oral and Maxillofacial Surgery and Oral Pathology of the University Hospital Vrije Universiteit/ACTA, Amsterdam, where he is partly
involved in clinical work and partly in the laboratory.
His research interest is mainly in the field of the clinical and pathological
aspects of oral cancer and precancer. He is author or co-author of approximately 160 papers, published in international scientific journals,
as well as (co)-author of approximately 100 papers in national scientific journals.
He served as President of the International Association
of Oral Pathologists from 1984-1986, and as President of the European Association of Oral Medicine from 1998-2000. Furthermore, he has
been Editor-In-Chief of the Dutch Scientific Journal of Dentistry (1986-1996). From 1978-1980 and from 1990-1992 he served as Dean of
the ACTA Dental Faculty in Amsterdam. Professor Van der Waal serves as Consulting Editor for several International scientific journals.
He has written chapters in the field of Oral Pathology in several books and is (co)-author and co-editor of books on "Oral Oncology",
"Oral Pathology", "The Burning Mouth Syndrome", 'Diseases of the Tongue", 'Diseases of the Jaws", "Diseases of the Salivary Glands",
and 'Histological Typing of Cancer and Precancer of the Oral Mucosa (1997)", the WHO monograph on 'Histological Typing of Odontogenic
Tumours" (1992) and 'Histological Typing of Oral Cancer and Precancer" (1997). Co-author of a Dutch book on "Oncology for the Dental
Profession" (1997).
Professor van der Waal is a member of various EC committees for the dental profession in the campaign "Europe
against Cancer" and the anti-tobacco program.
K. Warnakulasuriya, UKProfessor Saman Warnakulasuriya OBE, BDS (Cey), FDSRCS (Eng and Edin) PhD (Glasg) DSc
Professor of Oral Medicine and Experimental
Oral Pathology, King's College London
Consultant and Head of Oral Medicine, King's, Guy's and St Thomas' Hospitals' NHS Trusts, London
Director of the WHO collaboration Centre for Oral Cancer and Precaner in the United Kingdom
• Professor Warnakulasuriya
has published and lectured extensively on the subject of oral cancer and precancer from the levels of basic science to the management.
• He is an authority on global aspects of risk factors for oral cancer having conducted several field surveys in Europe, Asia
and Northern Africa. He was the principal investigator for the largest epidemiological study on oral cancer in young people in Southern
England. • In Collaboration with the World Health Organization he conducted several innovative studies on screening for oral
cancer. • Acted as a consultant to the International Agency for Research on Cancer (IARC) of the WHO to evaluate the carcinogenicity
of areca nut and of smokeless tobacco. • Senior advisor and member on the Editorial Boards of Oral Oncology (Sen Advisor)
, J Oral Medicine and Pathology and Int J of Clinical Dentistry. • His current research interests are: 1.
Evaluating screening tests, tumour and genetic markers for the early diagnosis 2. Examining risk profiles for oral cancer in different
populations 3. Sscreening for oral cancer and precancer and 4. The delivery and evaluation of interventional programs for oral precancer
including cessation of tobacco, areca nut usage and chemoprevention.
P. Allison, Canada
Dr. Paul Allison gained his BDS from University College London in 1986, following which he pursued specialist
training in oral and maxilla-facial surgery, completing his FDSRCS in 1990 and then further specialist training in dental public health,
completing his MSc at the University of London in 1994. He then moved to McGill University in Montreal and completed his PhD in 1998
and became Assistant Professor at the Faculty of Dentistry, McGill University, in 1999. He was promoted to Associate Professor in 2003
and became Director of the Quebec-based Oral and Bone Health Research Network in 2005 and Dean of the Faculty of Dentistry at McGill
in 2008. Throughout his career, he has received numerous peer-reviewed research grant and salary support awards. His research interests
include psychosocial issues as they relate to oral health, with a particular interest in understanding determinants of psychosocial health
outcomes and developing interventions to improve these outcomes in groups with chronic oral health problems. The groups he has particularly
focused on are head and neck cancer patients, those with Down syndrome and young children. His current head and neck cancer-related research
projects include an investigation of the interaction of biological and psychosocial factors along the life course as it relates to the
aetiology of squamous cell carcinoma, plus an investigation of the effectiveness of a coping strategies intervention for head and neck
cancer patients.
A. Awada, Belgium Ahmad AWADA, MD, PhD
Jules Bordet Institute Brussels, Belgium
Professor Ahmad Awada was born in Lebanon and studied Medicine at the Free University in Brussels (ULB), Belgium. He did a specialisation
in Internal Medicine and Medical Oncology at Jules Bordet Institute (under the supervision of Professor Jean Klastersky), in Brussels,
until 1992 ("La plus grande distinction"). During his specialisation, he also followed trainings in the clinical development of new therapies
and new anticancer drugs, under the supervision of Professor Martine Piccart.
To deepen his training, he stayed in the Netherlands
(New Drug Development Office, Free University, Amsterdam;) and in San Antonio, USA (Institute for Drug Development, under the direction
of Professor D. Von Hoff). He focused on the clinical development of new anticancer agents.
Back from the USA at the beginning of
1994, Doctor Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute,
Brussels. Since April 2005, he is the Head of the Medical Oncology Clinic. He has an important clinical activity in the treatment of
solid tumors. Doctor Awada took an active part in the development of new drugs, some of them already widely used.
Thanks to the recent
progress in technology and computer sciences, and consequently in molecular biology, we can understand better now how a cancer cell works
and how it becomes a cancer cell. Many drugs are now studied to block this process. Those are the molecular-targeted therapies, a subject
studied extensively in clinical research by Doctor Awada and were the basis for this thesis obtained from the ULB, Brussels, in 2004.
The aim of Doctor Awada, as far as research is concerned, is to look for new active anticancer drugs in solid tumors (new cytotoxics
and molecular targeted therapies), and to individualize the treatments according to the tumor characteristics.
SOCIETY MEMBERSHIPS:
• EORTC-NOCI Group (Network of Core Institutions) • EORTC-Melanoma Group • EORTC-Head and Neck Cancer Cooperative
Group • EORTC-Gynaecological Cooperative Group • Belgian Society of Medical Oncology • Membre du Conseil scientifique
du Forum de cancerologie en France • European Society of Medical Oncology (ESMO) • American Society of Clinical Oncology
(ASCO)
TEACHING RESPONSIBILITIES:
• Physical diagnosis demonstrations for medical students - Faculte de Medecine,
Universite Libre de Bruxelles (Academic Years 1990-1992, 1996-2005). • Member of College d'Enseignement pour l'obtention du
Diplome d'Etudes Specialisees (DES) en Cancerologie-U.L.B. • Assistant " charge d'exercices " (ASHU) - Faculte de Medecine,
Universite Libre de Bruxelles (2000-2005). • Professor at Ecole d'Infirmier(-ere)s de l'Universite Libre de Bruxelles: Principes
des traitements en Medecine: les tumeurs solides (16 heures) (2000-2001). • Formation Specialisee en Soins Infirmiers en Oncologie,
Ecole d'Ergologie de Belgique, Bruxelles, Annees Academiques 2002-2006. • Responsible of the " Grands Tours " at Jules Bordet
Institute • Interuniversitary Postgraduate Course of Medical Oncology (2004-2006)
Contact:
Dr Ahmad AWADA, MD,
PhD Jules Bordet Institute Medical Oncology Clinic Boulevard de Waterloo, 121 B-1000 Brussels Belgium Phone
: + 32 2 541 31 89 (secretary) Fax : + 32 2 538 08 58 E-mail : ahmad.awada@bordet.be
B. Braakhuis, The Netherlands
Boudewijn JM Braakhuis, PhD Boudewijn JM Braakhuis is senior investigator at the Section Tumor Biology,
Department of Otolaryngology / Head and Neck Surgery of the VU University Medical Center, Amsterdam, the Netherlands.
Professional
career:
1981-1986 Research fellow. Department of Otolaryngology / Head and Neck Surgery of the VU University Medical
Center, Amsterdam, the Netherlands.
1987 Ph.D. degree on the thesis , entitled: "Transplantation of human head and neck cancer
xenografts in athymic nude mice" . Promotor: Prof. G.B. Snow.
1986 Staff position (post-doc) Department of Otolaryngology
/ Head and Neck Surgery of the VU University Medical Center, Amsterdam, the Netherlands
1991 Assistant Professor position,
department of Otolaryngology / Head and Neck Surgery of the VU University Medical Center, Amsterdam, the Netherlands
2004
Associate Professor position, department of Otolaryngology / Head and Neck Surgery of the VU University Medical Center, Amsterdam, the
Netherlands
Research activities:
• Identification of the individuals most at risk for head and neck cancer • Identification of the hereditary components involved in head and neck carcinogenesis • Development of preventive/treatment
strategies for head and neck cancer • Molecular assessment multistep head and neck carcinogenesis • Genetic characterization
of second field tumors Publications: Dr Braakhuis has published over 100 papers (PubMed) in peer-reviewed journals. He is
member of the editorial board of "Oral Oncology" and is also reviewer for multiple cancer journals. Membership international
societies:
1987 American Association of Cancer Research (AACR)
1988-2000 Preclinical Therapeutic Models Group
(PTMG) of the EORTC
1995 Pharmacology and molecular mechanism group (PAMM) of the EORTC
1995-2001 European Science
Foundation Network on "Multiple primary oral cancer"
1996 Head and Neck cooperative Group of the EORTC
1997 Screening
and Pharmacology Group (SPG) of the EORTC
1998 Molecular Epidemiology Working Group (MEG) of the AACR
1999-2001 NIH/NCI
program "International Centers against oral cancer"
2000 International Society of Cancer Chemoprevention (IsCac)
P. Brennan, UKProfessor Peter Brennan has been a consultant Oral and Maxillofacial Surgeon at Portsmouth Hospitals NHS Trust since 2002. He is also
honorary Professor of Surgery and Head of the Academic Department of Surgery, at the University of Portsmouth. He qualified with honours
in both medicine (1994) and dentistry (1987) gaining distinctions and winning many prizes in subjects including anatomy, pharmacology,
anaesthetics, surgery, obstetrics and gynaecology and ophthalmology. He was awarded the gold medal for outstanding performance in the
intercollegiate exit FRCS examination in oral and maxillofacial surgery.
Peter Brennan's main clinical interests are head and neck
malignancy, reconstructive free flap surgery and neck lumps. In a research capacity, he has ongoing projects in both basic science and
clinical research. The basic science research is two-fold: the role of nitric oxide in oral cancer biology and adhesion molecules in
cancer. He is a research supervisor, an examiner for higher research degrees and has published over 70 papers to date covering many aspects
of oral and maxillofacial surgery, not exclusively cancer. He has recently had a paper published in Cancer Research, in collaboration
with Professor Salvador Moncada's laboratory at the Wolfson Institute, London.
Peter Brennan's research has been awarded both National
and International research prizes, and he has lectured extensively in the UK and abroad. He is an assessor for several grant awarding
bodies. He is committed to teaching and education, and has recently been appointed to the Court of Examiners at the Royal College of
Surgeons of England for the MRCS examination. He reviews for many general and specialist journals and is the Deputy Editor of the British
Journal of Oral and Maxillofacial Surgery. Peter has many outside interests but has a particular passion for the wines of Bordeaux and
Burgundy.
Born in Turin 05 June 1962. Graduate in Medicine in 1992 and specialised in Dentistry in 1995 at
the University of Turin, Italy. From 2000, Researcher at the Department of Biomedical Sciences and Human Oncology, Oral medicine Section,
University of Turin. From 2000, Appointed professor of Oral Medicine at the Dental School of University of Turin. Past Member of the
Councils of the European Association of Oral Medicine (2002-2004) and Past Member of the Council of the Italian Society of Oral Pathology
and Medicine (2000-2003) and Past Secretary of the same association (2003-2005) Member of the International Association of Oral Pathologist.
Grants Obtained 1998-1999: 1000 Euro for HLA-DR in patients with oral lichen planus with and without HCV infections (extracted
for M.U.R.S.T.[ex quota 60%] given to Prof.S-Gandolfo. 1990-2000: 4300 Euro, M.U.R.S.T.[ex quota 60%]:HLA-DQB allele in Italian patients
with mucous membrane pemphigoid 2000-2001: 4300 Euro M.U.R.S.T.[ex quota 60%]: Direct infection of the oral mucosa by HCV 2002:
100.000 Euro Oncological project S.Paolo with Prof.S.Gandolfo, Prof.L.Lo Muzio, Prof. GF.Favia, Prof. E.Majorano 2002: 5000 Euro
Regional research on the prevalence of oral cancer in liver, renal and bone-marrow transplanted patients with Prof.S.Gandolfo 2002-2003:
4300 Euro M.U.R.S.T.[ex quota 60%]: "Cytokine polymorphisms in mucous membrane pemphigoid" 2003-2004: 5041 Euro fondo M.U.R.S.T.[ex
quota 60%]:" Epitome mapping of BP180 antigen with Phage Display technique" 2004-2005: 8000 Euro Ricerca Regionale non finalizzata:
"Oral health and salivary and lacrimal glands status in HCV infected patients" with Prof.S.Gandolfo 2004-2005: 5563 Euro M.U.R.S.T.
[ex quota 60%]:" Real-time PCR of TNF-alpha and IFN-gamma and corrispondent polymorphisms in OLP patients with and without HCV infection"
Collaborations (International) 1. Prof. Stephen Porter, Prof. Crispian Scully, Eastman Dental Institute, London (UK): Oral lichen
planus and hepatitis viruses 2. Dr. Francesco Negro, University of Geneva (Swiss): Direct infections of oral mucosal by HCV in oral
lichen planus patients 3. Prof. Francesco Chiappelli, Dr.Paolo Prolo, UCLA, (USA): Psyneuroimmunology in OLP 4. Prof. Francina
Lozada-Nur, USFC, (USA): A multinational study on the prevalence on HCV in OLP patients
Collaborations (national) 1. Prof. PC.
Marchisio DIBIT, University of Milan, Integrins and oral cancer and precancer 2. Prof. A. Parodi, Dr. E.Cozzani, DISEM, University
of Genoa, Immunoblotting studies on pemphigus and mucous membrane pemphigoid (MMP); 3. Prof. A. Parodi, Dr. E.Cozzani, DISEM, University
of Genoa, p63 espression in oral cancer and OLP 4. Prof. Curtoni, Dept of Genetics, University of Turin, HLA-DR and DQ studies on
OLP and MMP 5. Prof. Curtoni, Dept of Genetics, University of Turin, Cytokine polymorphisms in OLP 6. Dr.P.Vescovi, Dr.M.Manfredi,
University of Parma, Lichenoid dysplasia and oral ereythema multiforme 7. Prof.C.Ferrari, Dr G.Missale, University of Parma, T-cell
function in OLP with HCV-infection 8. Prof.M.Rizzetto, Prof.A.Smedile, Dept of Gastroenterology, University of Turin: Sialadenitis
in HCV infected patients 9. Dott. Giovanna Zambruno, Dr Giovanni di Zenzo, IDI, IRCCS, University of Rome, BP180 mapping in patients
with MMP
Main research interest 1. OLP: etiology, management, neoplastic potential 2. Bullous Diseases: Immunology, management 3. Integrins and oral cancer and precancer 4. Extrahepatic manifestations of HCV
Service to Professional Publications Ad
Hoc Reviewer: Journal of Dental Research Ad Hoc Reviewer: British Journal of Dermatology Ad Hoc Reviewer: International Journal
of Dermatology Ad Hoc Reviewer: Journal of Oral Pathology and Medicine, Ad Hoc Reviewer: International Journal of Oral Maxillofacial
Surgery Ad Hoc Reviewer: Oral Oncology Ad Hoc Reviewer: Oral Diseases Ad Hoc Reviewer: Archive of Diseases of Children Ad
Hoc Reviewer: Journal of Epidemiology and Biostatistics Ad Hoc Reviewer:International Journal of Infectious Diseases Ad Hoc Reviewer:
Minerva Stomatologica. Ad Hoc Reviewer: Journal of the European Academy of Dermatology and Venereology Ad Hoc Reviewer: Human
Immunology
Other Professional Service 1992-1996 Resident in the Oral Medicine Section, Dental School, University of Turin 1996 - 1997 Appointed Professor of Oral Medicine, School of Specialization in Oral Surgery, University of Turin 1998-2000 Appointed
Professor of Oral Medicine, Chair of Clinical Dentistry, School of Dentistry, University of Turin 1996- current Clinical Professor,
Post-graduate course of Oral Medicine, School of Dentistry, University of Turin 1999-2001,2003 Clinical Professor, Post-graduate
course of Oral Medicine, School of Dentistry, University of Milan 2002 Clinical Professor, Master in Oral Medicine and Special Need,
School of Dentistry, University of Milan 2000-2002 Clinical Professor, Post-Graduate Course in Palliative Care , School of Medicine
, University of Turin 2003 Clinical Professor, Master in Palliative Care , School of Medicine , University of Turin
Publications
Article (English) 1. Gandolfo S,Carrozzo M,Carbone M,Broccoletti R,Cascio G,Humoral immunological parameters in Italian patients
with oral lichen planus. Bull Group Int Res Sci Stomatol et Odontol 1994;3-4:71-77 2. Gandolfo S,Carbone M,Carrozzo M,Gallo V,Oral lichen
planus and hepatitis C virus(HCV)infection:is there a relationship? A report of 10 cases.J Oral Pathol Med 1994;23:119-22 3. Carrozzo
M,Broccoletti R,Carbone M,Gandolfo S,Garzino-Demo P,Cascio G,Phenotypic analysis of pheripheral blood cell immunity in Italian patients
with different varieties of oral lichen planus. Bull Group Int Res Sci Stomatol et Odontol 1996;1-2:33-38 4. Carrozzo M, Gandolfo S,
Carbone M, Colombatto P, Broccoletti R, Garzino P, Ghisetti V. Hepatitis C virus infection in italian patients with oral lichen planus
: a prospective case control study. J Oral Pathol Med 25 (1996) 527-533 5. Carrozzo M, Carbone M, Gandolfo S, Valente G, Colombatto P,
Ghisetti V. An atypical verrucous carcinoma of the tongue arising in a patient with oral lichen planus associated with hepatitis C virus
infection. Oral Oncology 1997; 33: 220-225. 6. Lodi G, Carrozzo M, Hallett R, D'Amico E, Piattelli A, Teo CG, Gandolfo S, Carbone M,
Porter SR. HCV-genotypes in italian patients with HCV-related oral lichen planus. J Oral Pathol Med 1997; 26: 381-384. 7. Garzino-Demo
P, Carrozzo M, Trusulino L, Savoia P, Gandolfo S, Marchisio PC, Altered expression of *6 integrin subunit in oral squamous cell carcinoma
and oral potentially premalignant lesions. Oral Oncology 1998;34(3):204-210 8. Carbone M, Carrozzo M, Castellano S, Conrotto D, Broccoletti
R, Gandolfo S. Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial. Minerva Stomatol 1998; 47: 479-487
9. Carrozzo M, Gandolfo S, Lodi G, Carbone M, Garzino-Demo P, Carbonero C, Porter SR, Scully C. Oral Lichen planus in patients infected
or non infected with the hepatitis C virus: the role of autommunity. J Oral Pathol Med 1999;28:16-9 10. Carbone M, Conrotto D, Carrozzo
M, Broccoletti R, Gandolfo S, Scully C.Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management
of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999;
5:44-49 11. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis 1999;5:196-205 12. Scully C, Carrozzo M, Gandolfo
S, Puiatti P, Monteil R. Update on mucous membrane pemphigoid, a heterogeneous immune-mediated sub-epithelial blistering entity. Oral
Surg Oral Med Oral Pathol Oral Radiol End.1999; 88: 56-68 13. G Lodi, M Carrozzo,K Harris,A Piattelli,C G Teo, S Gandolfo,C Scully,S
R Porter. Hepatitis C virus-associated oral lichen planus: no influence from Hepatitis G virus co-infection. J Oral Pathol Med 2000;
29: 39-42 14. Pellicano R, Palmas F, Leone N, Vanni M, Carrozzo M, Gandolfo S, Puiatti P, Marietti G, Rizzetto M, Ponzetto M, Previous
tubercolisis, hepatitis c virus and lichen planus. A report of 10 cases. A causal or casual link? Panminerva Med 2000; 42:77-81 15. Scully
C, Eisen D, Carrozzo M. The management of oral lichen planus. Am J Clin Dermatol 2000; 1(5):287-306 16. Valente G, Pagano M, Carrozzo
M, Carbone M, Bobba V, Palestro G, Gandolfo S. Sequential immunohistochemical p53 expression in biopsies of oral lichen planus undergoing
malignant evolution. J Oral Pathol Med 2001;30:135-41 17. Carrozzo M, Francia di Celle P, Gandolfo S, Carbone M, Conrotto D, Fasano ME,
Roggero S, Rendine S, Ghisetti V. Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus associated oral lichen
planus. Br J Dermatol 2001; 144(4):803-8 18. Carrozzo M. Oral health in patients with hepatitis C virus infection: an underestimated
problem? Oral Dis 2001; 7(5):267-70 19. Carrozzo M, Fasano ME, Broccoletti R, Carbone M, Cozzani E , Rendine S, Roggero S, Parodi A,
Gandolfo S. HLA-DQB1 alleles in Italian patients with mucous membrane pemphigoid predominantly affecting the oral cavity. Br J Dermatol
2001; 145(5):805-8 20. Bez C, Carrozzo M, Lodi G, Gandolfo S, Carrassi A, Scully C, Porter SR. Lack of association between transfusion
trasmitted virus and oral lichen planus in British and Italian populations. Br J Dermatol 2001;145(6):990-3 21. Gandolfo S, Carrozzo
M. Lichen planus and hepatitis C virus.Minerva Gastroenterol Dietol 2002: 48: 89-97 22. Prolo P, Chiappelli F, Cajulis E, Bauer J, Spackman
S, Romeo H, Carrozzo C, Gandolfo S, Christensen R. Psychoneuroimmunology in Oral Biology and Medicine: The Model of Oral Lichen Planus.
Proc NY Acad Sc 2002; 966: 429-40 23. Carbone M, Carrozzo M, Pentenero M, Gandolfo S. Malakopakia of the tongue. A case report and review
of the literature. Panminerva Med 2002 Jun;44(2):159-61 24. Castellano S, Carbone M, Carrozzo M, Broccoletti R, Pagano M, Ciocca Vasino
MA, Gandolfo S. Onset of oral extranodal large b-cell non-hodgkin's lymphoma in a patient with polycythemia vera: a rare presentation.
Oral Oncol 2002;38:624-6 25. Carrozzo M, Qadri R, Latorre P, Pentenero M, Bertolusso G, Paganin S, Gandolfo S, Negro F. Molecular evidence
that hepatitis C virus replicates in the oral mucosa. J Hepatol 2002;37: 364-9 26. Pilli M, Penna A, Zerbini A, Vescovi P, Manfredi M,
Negro F, Carrozzo M, Mori C, Giuberti T, Ferrari C, Missale G. Oral lichen planus pathogenesis: A role for the HCV-specific cellular
immune response.Hepatology. 2002 Dec;36(6):1446-1452 27. Carrozzo M, Gandolfo S. Oral diseases possibly associated with hepatitis C virus.
Crit Rev Oral Biol Med 2003; 14 (2): 115-127 28. Pentenero M, Carrozzo M, Pagano M, Galliano D, Broccoletti R, Scully C, Gandolfo S.
Oral mucosal dysplastic lesions and early squamous cell carcinomas: underdiagnosis from incisional biopsy. Oral Dis 2003; 9:68-72 29.
Carbone M , Goss E , Carrozzo M, Castellano S, Conrotto D, Gandolfo S. Systemic and topic corticosteroid treatment of oral lichen planus:
a comparative study with long-term follow-up. J Oral Pathol Med 2003; 32:323-329 30. Gandolfo S. , Richiardi L, Carrozzo M. , Broccoletti
R, Carbone M. , Pagano M., Vestita C., Rosso S., Merletti F. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus:
a follow-up study in an Italian population. Oral Oncol 2003; Oral Oncol 2004:40: 77-83 31. Carrozzo M, Uboldi de Capei F, Dametto E,
Fasano ME, Arduino P, Broccoletti R, Vezza D, Rendine S, Curtoni ES, Gandolfo S .Tumor necrosis factor- and interferon- polymorphisms
contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004;122: 87-94 32. Pentenero M, Carrozzo M, Pagano M, Gandolfo
S. Oral acanthosis nigricans, tripe palms and sign of Leser-Trelat in a patients with gastric adenocarcinoma. Int J Dermatol 2004; 43:530-532
33. Carrozzo M, Cozzani E, Broccoletti R, Carbone M, Pentenero M, Arduino P, Parodi A, Gandolfo S .Analysis of antigens targeted by circulating
IgG and IgA antibodies in patients with mucous membrane pemphigoid predominantly affecting the oral cavity. J Periodontol 2004;75:1308-1314
34. Cozzani E, Drosera M, Parodi A, Carrozzo M, Gandolfo S, Rebora A. Frequency of IgA antibodies in pemphigus , bullous pemphigoid and
mucous membrane pemphigoid. Acta Dermatol Venereol 2004 ; 84(5):381-384 35. Campisi G, Giovannelli L, Ammatuna P, Capra G, Colella G,
Di Liberto C, Gandolfo S, Pentenero M, Carrozzo M, Serpico R, D'angelo M. Proliferative verrucous vs conventional leukoplakia: no significantly
increased risk of HPV infection. Oral Oncol 2004; 40: 835-840 36. Gandolfo S, Carrozzo M, Pagano M. Oral lichenoid reactions: what are
they? Oral Oncol 2004;40:1057-1058 (Letter) 37. Carrozzo M., Brancatello F. , Dametto E. , Arduino P. , Pentenero M. , Rendine S. , Porter
S.R. ,Lodi G, Scully C. , Gandolfo S. Hepatitis C Virus-associated Oral Lichen Planus: is the Geographical Heterogeneity related to HLA-DR6?
J Oral Pathol Med 2005;34: 204-208 38. Scully C, Bagan JV, Black M, Carrozzo M, Eisen D, Escudier M, Farthing P, Kuffer R, Lo Muzio L,
Mignogna MD, Porter SR. Epithelial biology. Oral Dis 2005;11: 58-71 39. Lodi G,Scully C,Carrozzo M, Griffiths M, Sugerman PB, Thongprasom
K. Current controversies in oral lichen planus: report of an international consensus meeting - Part 1. Viral infections and aetiopathopathogenesis.
Oral Surg Oral Med Oral Pathol Oral Radiol End 2005: 100(1):40-51 40. Lodi G,Scully C,Carrozzo M, Griffiths M, Sugerman PB, Thongprasom
K. . Current controversies in oral lichen planus: report of an international consensus meeting - Part 2. Clinical management and malignant
transformation. Oral Surg Oral Med Oral Pathol Oral Radiol End 2005:100: 164-170 41. Pentenero M, Gandolfo S, Carrozzo M. Importance
of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: A review of the literature.
Head Neck. 2005 ;27:1080-91 42. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V oral lichen planus: clinical features
and management. Oral Dis. 2005 Nov;11(6):338-49 43. Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, Pentenero M, Gandolfo
S. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled
trial.Br J Dermatol 2006;154:139-145 44. Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M, Scully C. Toluidine blue uptake
in potentially malignant oral lesions in vivo: Clinical and histological assessment. Oral Oncol. 2006;00-00
Article (Italian) 1.
Gandolfo S,Gallo V,Carbone M,Zulian P,Carrozzo M, Lichen planus orale e patologia epatica. Parte I- Prevalenza di danno epatico in una
casistica di 96 pazienti portatori di lichen planus orale. Minerva Stomatol 1992;41:203-207 2. Gandolfo S,Carbone M,Zulian P,Broccoletti
R,Carrozzo M,Lichen planus orale e patologia epatica.Parte II-Correlazioni clinico-statistiche tra manifestazioni orali e danno epatico.
Minerva Stomatol 1992;41:209-213 3. Gandolfo S,Carbone M,Carrozzo M,Candidosi orale quale prima manifestazione di infezione da HIV(Human
immunodeficiency virus).Analisi di due casi. Minerva Stomatol 1992;41:227-231 4. Gandolfo S,Carbone M,Carrozzo M,Scamuzzi S,Tecniche
bioptiche in oncologia orale:biopsia escissionale od incisionale? Revisione critica della letteratura e contributo personale. Minerva
Stomatol 1993;42:69-75 5. Gandolfo S,Broccoletti R,Carbone M,Carrozzo M,Mattea A,Scamuzzi S,Zulian P,La gestione informatizzata degli
archivi clinici in patologia orale.Odontostomatologia 1993; 4:689-693 6. .Carrozzo M,Carbone M,Gandolfo S,Stomatite aftosa ricorrente:attuali
concetti eziopatogenetici e terapeutici. Minerva Stomatol 1995;44 :467-475 7. Carbone M,Carrozzo M,Broccoletti R,Mattea A,Gandolfo S,Il
trattamento topico del lichen planus orale atrofico-erosivo con fluocinonide in gel bioadesivo,clorexidina e miconazolo gel. Un trial
aperto. Minerva Stomatol 1996; 45: 61-68 8. Broccoletti R, Mattea A, Carbone M, Carrozzo M, Gandolfo S, Garzino P, Riva F, Succo G. A
five year prevention trial of oral cavity tumors in Turin Acta Oncol 16 (1995) 389-402. 9. Carrozzo M,Broccoletti R,Carbone M,Gandolfo
S,Garzino-Demo P,Il Pemfigoide delle membrane mucose. Aspetti clinici,istopatologici,immunologici ed attuali orientamenti terapeutici.Minerva
Stomatol 1996;45:455-463 10. Garzino-Demo P, Carbone M, Carrozzo M, Diagnostica differenziale tra le osteomieliti ed osteolisi neoplastiche
delle ossa mascellari: revisione della letteratura e caso clinico. Dentista Moderno 1996; 8: 1197-1183 11. Serra R, Carrozzo M, Conrotto
D, Ghisetti V, Marchiaro G, Significato prognostico della colonizzazione da Candida di lesioni del cavo orale. Microbiologia Medica 1996;
11(3): 228-232 12. Garzino-Demo P, Carbone M, Carrozzo M, Broccoletti R, Gandolfo S, Melanomi del cavo orale. Revisione della letteratura.
Minerva Stomatol 1997; 46: 329-335 13. Carrozzo M, Gandolfo S, Carbone M, Carbonero C, Colombatto P, Broccoletti R, Garzino P, Ghisetti
V, Infezione da virus dell'epatite C e lichen planus orale: una significativa associazione. Medicina Subalpina 1997; 2: 10-12 14. Carbone
M, Carrozzo M, Conrotto D, Garzino-Demo P, Broccoletti R, Gandolfo S, Il trattamento topico del lichen planus orale atrofico-erosivo
con clobetasolo in gel bioadesivo, soluzione di clorexidina e miconazolo gel orale. Minerva Stomatol 1997; 46: 423-428 15. Carrozzo M,
Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S, Il trattamento del pemfigoide delle membrane mucose: descrizione ed analisi di
11 casi. Minerva Stomatol 1997;46:553-559 16. Sottosanti M, Pezzoli M, Carrozzo M, Studio sulla resistenza alla compressione di radici
costruite con perno moncone adattato al canale con precisione o scaricato. Minerva Stomatol 1997; 46: 649-657 17. Garzino-Demo P, Carbone
M, Carrozzo M, Broccoletti R, Gandolfo S. Aumento di volume gengivale indotto da farmaci (fenitoina, ciclosporina e calcio antagonisti).
Revisione della letteratura. Minerva Stomatol 1998; 47:387-398 18. Carrozzo M, Togliatto M, Gandolfo S. Eritema multiforme: un fenotipo
patologico eterogeneo. Minerva Stomatol 1999; 48:217-226 19. Togliatto M, Carrozzo M, Conrotto D, Pagano M, Gandolfo S. Lupus eritematoso
orale.Descrizione ed analisi di 11 casi. Minerva Stomatol 2000; 49: 35-40 20. Pentenero M, Carrozzo M, Broccoletti R. Algie facciali
e lesioni vescicolo-erosive. Dent Cadmos 2001; 15: 13-14 21. Carbone M, Traversa G, D'Angeli G, Carrozzo M. Terapia medica delle candidosi
orali. Italian Oral Surgery 2005; 4:51-55
Books (Italian) 1. Gandolfo S, Scully C, Carrozzo M. Patologia e medicina del cavo orale.
UTET, Torino, 2001. 2. Gandolfo S, Carrozzo M, Brocccoletti R, Carbone M, Pentenero M. Xerostomia e Ipofunzione delle ghiandole salivari.
Tiziano Cornegliani Editore, Peschiera Borromeo (Milano), 2002
Chapters in books (English) 1. Carrozzo M,Carbone M,Gandolfo S, Lichen Planus and Lichenoid reactions.In:Porter
S,Scully C,"Innovations and developments in non-invasive orofacial health care",Science Review Northwood 1996;97-108 2. Broccoletti R,
Carrozzo M, Carbone M, Garzino-Demo P, Gandolfo S, A new computer aided method evaluating toluidine blue staining in oral cancer and
precancer. In: Oral Oncology, volume V,Varma AK ed. 1997: 124-127 3. Garzino-Demo P, Carrozzo M, Carbone M, Broccoletti R, Trusulino
L, , Gandolfo S, Marchisio PC, Expression of integrins and basement membrane proteins in oral squamous cell carinoma and oral precancerous
lesions: an immunohistochemical and western blotting study. In: Oral Oncology, volume V,Varma AK ed. 1997:586-589
Chapters in books
(Italian) 1. Carrozzo M, Gandolfo S. Alterazioni del cavo-oro-faringeo in pazienti in cure palliative. In: Vignotto F, De Luca A,
Bertetto O, Ciuffreda L. Corso di perfezionamento in cure palliative. Scienza medica, Torino, 2002: 301-312 2. Preti G, Riabilitazione
Orale, UTET, Torino,2003 3. Carrozzo M, Arduino P. Malattie infiammatorie ed infettive delle mucose orali . In Modica R Trattato di Odontoiatria,
Minerva Medica Torino 2004
Dr. Elad is the Head of the Oral Medicine Service at the Hospital, Department of Oral Medicine, Hebrew University
- Hadassah School of Dental Medicine. She established and runs this clinical service at the Hadassah University Hospital with special
attention to the Departments of Oncology, Haematology and Bone Marrow Transplantation and Pediatric Haemato-oncology.
In addition
she is the Head of a two year course for the senior undergraduate students, Dental Management of Medically Complex Patients. She also
is the Head of a Continuing Education Course on the subject of Dental Management of Medically Complex Patients as part of the Israeli
Dental Association Program.
Dr. Elad is the Chairperson of the Israeli Society of Oral Medicine; Secretary of the International Society
of Oral Medicine; a member of the Israeli Board of Oral Medicine, Israeli Ministry of Health and Israeli Dental Association; and a member
of the Israeli Academic Committee for Oral Pathology, Israeli Ministry of Health and Israeli Dental Association.
Her main research
interests are oral medicine, oral oncology, oral pathology and special care dentistry. She is actively involved in multi-center studies
as a Principal Investigator and as a research collaborator. She is the Principal Investigator of a study of oral graft versus host disease
enrolling patients in 35 European countries. She is the Head of the Working Section on Viral Infections in Cancer Patients of the Multinational
Association of Supportive Care in Cancer / International Society of Oral Medicine (MASCC/ISOO), a member of the Working Section on Oral
Graft Versus Host Disease of the MASCC/ISOO and a member of the Oral Mucositis Study Group of MASCC/ISOO.
Dr. Elad's interests in
oral cancer and oral complications in cancer patients have directed her field of research. Preventive oral care protocols for cancer
patients, dental treatment of cancer patients, new modalities for management of chemotherapy and radiotherapy induced oral complications
and innovative drugs for the management of graft versus host disease are some examples of such research projects.
She has presented
her research in numerous scientific events around the world, including invited lectures at prestigious universities and national dental
societies. She has published numerous research works including original research papers, review articles, and chapters in books.
Dr.
Elad is also active in the Postgraduate Clinic for Oral Medicine, at the Department of Oral Medicine, Hebrew University, Hadassah School
of Dental Medicine. In this clinic she provides appropriately modified dental care to medically complex patients including oncology and
haematology patients.
Education Wayne State University, Detroit, MI, B.S., 1970, Biology/Chemistry Wayne State University, Detroit, MI, M.S.,
1973, Physiology Wayne State University, School of Medicine Detroit, MI, M.D., 1977, Medicine
Training 1977-1978 Internship
in Internal Medicine, Department of Internal Medicine, Wayne State Univ., Detroit, MI 1978-1980 Residency in Internal Medicine, Department
of Internal Medicine, Wayne State Univ., Detroit, MI 1980-1981 Chief Resident, Department of Internal Medicine, Harper Hospital,
Wayne State Univ., Detroit, MI 1981-1983 Fellowship in Oncology, Department of Internal Medicine, Wayne State Univ., Detroit, MI
Faculty Appointments 1971-1973 Teaching Assistant, Department of Biology, Wayne State University, Detroit, MI. Courses
Taught: Comparative Anatomy and Physiology I and II, General Biology Laboratory, Advanced Instrumentation Laboratory 1972-1979 Instructor,
Department of Biology, Wayne County Community College, Detroit, MI. Courses Taught: Anatomy and Physiology I and II, Lecture Laboratory,
General Biology 1983-1989 Assistant Professor of Medicine, Department of Internal Medicine, Division of Hematology Oncology, Wayne
State University School of Medicine, Detroit, MI 1989-Present Associate Professor of Medicine, Department of Internal Medicine, Division
of Hematology Oncology, Wayne State University School of Medicine, Detroit, MI 1992-Present Adjunct Member of the Graduate faculty,
Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, MI. 1993-Present Faculty of Cancer Biology
Graduate Program, Wayne State Univ. School of medicine, Detroit, MI 1994-Present Professor of Medicine, Department of Internal Medicine,
Division of Hematology-Oncology, Wayne State University, Detroit, MI. 1997-Present Professor of Oncology and member Karmanos Cancer
Institute, Detroit, MI. 2000- Present Professor Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, Mi.
Honors 1971-1973 Wayne State University, Teaching Fellowship Award 1973-1974 Wayne State University Medical School, Scholarship Award 1981-1983 American Cancer Society Clinical Fellowship Award 1987-Present Fellow, American College of Physicians 1994
Recipient, University Presidents Bonus Award, Wayne State University. 1996-2008 Selected "Best Doctors in America", Woodward/White,
Inc. 1999 Alpha Omega Alpha Honor Medical Society 1999 Wayne State University College Teaching Award 2000 Wayne State University
- 20 year Faculty Award 2003 Wayne State University, Distinguished Alumni Award
Societies 1983-Present Southwest Oncology
Group 1983-Present Member, American College of Physicians 1984-Present American Society of Clinical Oncology 1987-Present
Fellow, American College of Physicians 1989-Present American Assoc. for Cancer Research
Licensure and Board Certification Licensure - State of Michigan - Permanent I.D. number 041899 National Board Medical Examiners, Parts I, II, III, 1978 Diplomate,
American Board Internal Medicine, September 1982 Diplomate, American Board of Oncology, November 1983
Publications (selected
from recent publications Ensley J., Maciorowski Z., Hassan M., Pietraszkiewicz H., Sakr W., Hielbrun L. Variations in DNA
aeuploid cell content during tumor dissociation in human colon and head and neck cancers analyzed by flow cytometry. Cytometry, 14:550-558,
1993. Ensley, J., Maciorowski, M. Clinical appliction of DNA content parameters in patients with squamous cell carcinomas of the
head and neck. Seminars in Oncology, 21:330-339, 1994. Ensley JF. The clinical application of DNA content and kinetic parameters
in the treatment of patients with squamous cell carcinomas of the head and neck. Cancer and Metastasis Review 15:133 141, 1996. Shridhar
R, Shridhar V, Rivard S, Siegfried JM, Pietraszkiewicz H, Ensley JF, Pauley R, Grignon D, Sakr W, Miller OJ, Smith DI. Mutations in the
arginine rich protein (ARP) gene in lung, breast prostate cancers and in squamous cell carcinomas of the head and neck. Cancer Research,56:5576-78,
1997. Yeudall WA, Jakus J, Ensley JF, Robbins KC. Functional characterization of p53 molecules expressed in human squamous cell carcinomas.
Molecular Carcinogenesis, 18:89-96, 1997. Massimo Cardinali F, Kratochvil J, Ensley JF, Robbins KC, Yeudall WA. Functional characterizayion
in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck.Molecular Carcinogenesis,18:78-88, 1997. Patel
V, Jakus J, Harris CM, Ensley JF, Robbins KC, Yeudall A. Altered expression and activity of G1/S cyclins and cyclin dependent kinases
characterize squamous cell carcinomas of the head and neck.Int J.Cancer, 75: 551-555, 1997. Patel V, Jakus J, Harris CM, Ensley JF,
Robbins KC, Yeudall A. Altered expression and activity of G1/S cyclins and cyclin dependent kinases characterize squamous cell carcinomas
of the head and neck. Int J. Cancer, 75: 551-555, 1997. Lesaca EE, Ensley JF, Yeudall WA. Cellular factors may enable squamous carcinoma
cells to overcome TGF-B mediated repression of CDK2 activity. Eur. J. Cancer, 34:52-57, 1998. Al Sarraf M, LeBlanc M, Giri S, Fu
K, Cooper J, Voung T, Forastiere A, Adams G, Sakr W, Schuller D, Ensley J. Superiority of Chemo Radiotherapy vs Radiotherapy in patients
with locally advanced nasopharyngeal cancer. Preliminary results of Intergroup randomized study. JCO, 16:1310-1317 1998.
J. Epstein, USA
JOEL EPSTEIN, DMD, MSD, FRCD University of Washington, Seattle, Washington USA
Professor Joel B. Epstein qualified
at the University of Saskatchewan, Saskatoon, Canada, in 1976. He completed an externship in diagnosis and hospital dentistry at the
University of Toronto and an Oral Medicine Residency at the University of Washington, Seattle, Washington. Upon completion of the Oral
Medicine Graduate Program he was awarded a Master of Science in Dentistry in 1979. He was on Faculty at the University of Saskatchewan,
Saskatoon, Canada from 1979 to 1981 directing the Division of Oral Medicine and Diagnosis. In 1981 he was appointed to the medical/dental
staff of the British Columbia Cancer Agency and to the staff of Vancouver General Hospital in Vancouver, Canada. He became Head of the
Department of Dentistry and the Division of Oral Medicine and Clinical Dentistry at Vancouver Hospital as well as held an appointment
at the University of British Columbia. He conducted a private practice in Oral Medicine in Vancouver. When Oral Medicine was recognized
as a specialty of the College of Dental Surgeons of British Columbia he was admitted to this specialty designation, and when national
recognition of the specialty of Oral Medicine and Pathology in Canada was completed, he was awarded a Fellow of the Royal College of
Dentists of Canada in Oral Medicine. He is a Diplomate of the American Academy of Oral Medicine and serves as an Examiner of the Board.
He is currently Professor of Oral Medicine at the University of Washington in Seattle, Washington and Director of the Graduate Program
in Oral Medicine and Dental Care for the Disabled Program at the University of Washington and on the medical-dental staff of the British
Columbia Cancer Agency. He is currently the President of the International Society for Oral Oncology.
His research interests have
included general aspects of Oral Medicine, with a focus on oncology. This research has included study of oral candidiasis, prevention
and management of oral herpes virus infections, caries prevention in head and neck cancer patients, management of hyposalivation, treatment
and classification of oral Kaposi's sarcoma. In specific complications of cancer therapy, Dr. Epstein has studied osteoradionecrosis,
oral presentation of malignant disease in the oral cavity and head and neck, oral mucositis, oral premalignant lesions and quality of
life in cancer patients. Intervention studies with topical therapies for management of premalignant oral mucosal disease and investigation
of loss of heterozygosity of putative tumor suppressor genes in oral premalignancy are recent interests. He continues to study oral topical
therapies for mucositis, candidiasis, mucosal pain and mucosal premalignant lesions.
Dr. Epstein has published more than 300 scholarly
works including over 200 papers in refereed journals, over 60 abstracts and letters, and contributed to a number of textbooks and review
publications.
Dr. Epstein is on the Editorial Review Board of Oral Oncology, Oral Diseases, Oral Surgery Oral Medicine Oral Pathology
Oral Radiology and Endodontics, International Journal of Oral and Maxillofacial Surgery, Canadian Dental Journal, and Special Care in
Dentistry.
J. Fagan, South Africa
Professor Johan Fagan is a graduate of the University of Cape Town. He completed his Otolaryngology training at
the same institution in 1993. He subsequently completed a 6-month head and neck surgery clinical fellowship at the Royal Marsden Hospital
in London, and 1-year clinical fellowships at the University of Pittsburgh in Head and Neck/Cranial Base surgery, and in Otology/Neurotology.
He has been professor and chairman of the Division of Otolaryngology of the University of Cape Town since 2002. He is a corresponding
member of the American Head and Neck Society. He has authored/coauthored about 75 papers and book chapters. His department has a strong
mission to improve ENT services in Sub-Saharan Africa. He established the ?University of Cape Town Karl Storz Fellowship in Advanced
Head and Neck Surgery?, which trains head and neck surgeons from Sub-Saharan Africa, and has a residency programme for ENT surgeons from
Africa. His department is the Karl Storz Training Center for Sub-Saharan Africa.
S. Franceschi, France
Silvia FRANCESCHI International Agency for Research on Cancer 150, Cours Albert Thomas F-69372
Lyon cedex 08 France Tel: 33-(0)4-72.73.84.02 Fax: 33-(0)4.72.73.83.45 E-mail: franceschi@iarc.fr
Dr Silvia Franceschi
was born in Milan, Italy, where she was trained as an MD (University of Milan, 1979) and gynaecologist (1983). Since medical school she
has been interested in epidemiology and statistics, and obtained a Post-graduate Diploma in Medical Statistics (University of Pavia,
1987).
Between 1981 and 1983 she was Research Fellow at the Division of Epidemiology of the Imperial Cancer Research Fund, Oxford,
UK, where, under the supervision of Sir Richard Doll, she obtained a Master Degree in Epidemiology.
Her M.Sc. thesis, in 1983, was
one of the earliest studies of the role of papillomavirus in the aetiology of cervical cancer. Back in Italy she developed, firstly in
Milan, at the "Mario Negri" Institute for Pharmacological Research, and later at the Aviano Cancer Center, a network of case-control
studies that included numerous cancer sites (breast, colon, ovary, upper aero-digestive tract, HIV-associated malignancies) and risk
factors (female hormones, alcohol, diet, viruses).
After having directed the Epidemiology Unit of Aviano Cancer Center between 1984
and 2000, she became the Chief of the Unit of Field and Intervention Studies at the International Agency for Research on Cancer (IARC),
Lyon, France. In the context of IARC, she has chiefly been involved in studies on infectious diseases and cancer, most notably papillomavirus
and cervical and oral cancer, HIV and hepatitis C virus and lymphomas, and Helicobacter pylori and stomach cancer. All her studies involve
broad international collaboration, mainly with Latin-America, Asia and Africa. Over the years she has closely collaborated with several
research centers in the United States (National Cancer Institute) and Oxford, especially in respect to meta-analyses and pooled analyses
(e.g., cancers of the breast, thyroid, and cervix). She is the author or co-author of over 700 publications in peer-reviewed journals.
R. Haddad, USARobert I. Haddad, MD, is Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts. He is Clinical Director/Head
and Neck Oncology Program, and a member of the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dr. Haddad received his medical degree from Saint Joseph University, French Faculty of Medicine, and served as intern and resident
at St. Luke's Roosevelt Hospital Center, New York, New York. He served a fellowship in hematology/oncology at Greenebaum Cancer Center,
University of Maryland, Baltimore, Maryland. Dr. Haddad is a member of several professional societies, including the American Society
of Clinical Oncology, American Association for Cancer Research, Cancer and Leukemia Group B, and the American Society for Therapeutic
Radiology and Oncology.
Dr. Haddad's current research activity involves the use of intensive chemoradiotherapy regimens for patients
with locally advanced head and neck cancer with particular attention to radioprotection. He is also involved in a large phase III study
comparing sequential chemoradiotherapy to concomitant chemoradiotherapy: The Paradigm Trial. Other initiatives currently being developed
include collaboration with the NCI/CTEP to develop a phase II study looking at the use of depsipeptide in head and neck cancer, as well
as looking at new molecules in head and neck cancer treatment. Dr. Haddad lectures extensively on head and neck cancer, both on the
regional ,national and international level.
M. Hashibe, FranceMia Hashibe
Ph.D. Scientist Lifestyle, Environment and Cancer Group Genetics and Epidemiology Cluster International Agency
for Research on Cancer 150 cours Albert Thomas 69008 Lyon France Phone: +33 (0) 4 72 73 80 32 Fax: +33 (0) 4 72 73
83 20 Email: hashibe@iarc.fr
EDUCATION Ph.D., UCLA School of Public Health, Department of Epidemiology, 2002 M.P.H.,
UCLA School of Public Health, Department of Epidemiology, 1999
SELECTED PUBLICATIONS 1. Boffetta P, Hashibe M.
Alcohol and Cancer. Lancet Oncology 2006 Feb;7(2):149-56. 2. Hashibe M, Boffetta P, Zaridze D, Szeszenia-Dabrowska N, Mates
D, Janout V, Fabianova E, Bencko V, Brennan P. Evidence for an important role of alcohol and aldehyde metabolizing genes in head and
neck cancer susceptibility. Cancer Epidemiology, Biomarkers and Prevention 2006 Apr; 15(4):696-703. 3. Hashibe M, Morgenstern
H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, Mack TM, Greenland S. Marijuana use and the risk of lung and upper aerodigestive-tract cancers:
results of a population-based case-control study. Cancer Epidemiology, Biomarkers and Prevention 2006 Oct; (15)10. 4. Hashibe
M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Wunsch-Filho V, Fernandez L, Franceschi
S, Hayes R, Herrero R, Koifman S, La Vecchia C, Lazarus P, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan A, Rudnai
P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei QY, Winn DM, Zaridze D, Zatonski W, Zhang ZF, Berthiller
J, Boffetta P. Alcohol drinking in never users of tobacco and cigarette smoking in never drinkers, and the risk of head and neck cancer:
pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Journal of the National Cancer Institute
2007 May; 99(10):777-789. 5. Hashibe M, McKay J D, Curado M P, Oliveira J C, Koifman S, Koifman R, Zaridze D, Shangina O,
Wunsch-Filho V, Eluf-Neto J, Levi J E, Matos E, Lagiou P, Lagiou A, Benhamou S, Bouchardy C, Szeszenia-Dabrowska N, Menezes A, Dall'Agnol
M M, Merletti F, Richiardi L, Fernandez L, Lence J, Talamini R, Barzan L, Mates D, Mates I N, Kjaerheim K, Macfarlane G J, Macfarlane
T V, Simonato L, Canova C, Holcatova I, Agudo A, Castellsague X, Lowry R, Janout V, Kollarova H, Conway D I, McKinney P A, Znaor A, Fabianova
E, Bencko V, Lissowska J, Chabrier A, Hung R J, Gaborieau V, Boffetta P, Brennan P. Multiple ADH genes are associated with upper aerodigestive
cancers. Nat Genet 2008; Jun;40(6):707-9.
A. High, UKDr Alec High is currently Senior Lecturer and Honorary Consultant in Pathology at the University of Leeds. He is a member of the Diagnostic
Services Head & Neck Pathology Team at the Leeds NHS Teaching Trust with a remit for Oral, Maxillofacial, ENT and Thyroid pathologies
in the region. He is Visiting Professor to a number of Overseas Universities and is currently Honorary Secretary to the British Society
of Oral & Maxillofacial Pathology. He has published over 100 papers in refereed journals and has active research interests in cancer,
especially basal cell nevus syndrome and antimicrobial peptides.
He is on the Editorial Review Board of BJOMS, and reviews submissions
for a number of other publications and funding bodies, particularly Histopathology, the Journal of Pathology and Archives of Oral Biology.
He is a serving examiner for the MRCPath at the Royal College of Pathologists.
M. Iwase, JapanMasayasu Iwase, DDS, PhD Department of Oral and Maxillofacial Surgery, Showa University School of Dentistry 2-1-1, Kitasenzoku, Ota-ku,
Tokyo, 145-8515, Japan Tel: 81-3-3787-1151 Fax: 81-3-5498-1543 E-mail: iwase@senzoku.showa-u.ac.jp
Education
Showa University School of Dentistry, Tokyo, DDS, 1983. Showa University, Tokyo, PhD, 1987.
Faculty Appointment 1987-88,
Lecturer in Second Department of Oral and Maxillofacial Surgery, Showa University School of Dentistry 1988-90, Visiting Assistant Professor
in Department of Pathology, University of Pennsylvania School of Dental Medicine 1990, Lecturer in Second Department of Oral and Maxillofacial
Surgery, Showa University School of Dentistry 1991-2004, Assistant Professor in Second Department of Oral and Maxillofacial Surgery,
Showa University School of Dentistry 2004-present, Assistant Professor in Department of Oral and Maxillofacial Surgery, Showa University
School of Dentistry
Research Theme Study of PI3-K/Akt, EGFR, HDAC and proteasome inhibitors for oral squamous cell carcinoma
as molecular target therapies Study of signaling pathways of TRAIL and Fas-L-mediated apoptosis for oral squamous cell carcinoma Analysis
of host defense system, including neutrophil function during the perioperative periods for oral cancer
Memberships International
Association of Oral and Maxillofacial Surgeons Asian Association of Oral and Maxillofacial Surgeons Japanese Society of Oral and Maxillofacial
Surgeons Japanese Stomatological Society The Japanese Cancer Association Japan Society of Clinical Oncology Japan Society for Head and
Neck Cancer The Japanese Association for Molecular Target Therapy of Cancer Japanese Society of Oral Therapeutics and Pharmacology The
Japanese Society for Jaw Deformities The Japanese Society for Oral Mucous Membrane Japanese Academy of Maxillofacial Implants Japanese
Society for Immunology The Japanese Society of Inflammation and Regeneration The Japanese Society for Regenerative Medicine
D. Keefe, Australia
Professor Keefe is Clinical Director of the Royal Adelaide Hospital Cancer Centre, and The Cancer Council SA Professor
of Cancer Medicine at the University of Adelaide. She is Head of the Mucositis Research Group in the Hanson Institute, and Chairman
of the Mucositis Study Group of the Multinational Association for Supportive Care in Cancer (MASCC). She is a Board member of TCCSA and
of MASCC. Her other roles include Deputy Chair of the SA Cancer Network Steering Committee, and Chair of the MBBS Curriculum Committee
Operations.
Dorothy Keefe graduated in Medicine (MBBS) from the University of London in 1986. She migrated to Australia in 1988,
where she undertook her Physician Training in General Medicine and Medical Oncology at the Queen Elizabeth Hospital in South Australia.
She became a Fellow of the Royal Australasian College of Physicians (FRACP) in 1996, and received her Doctorate of Medicine from the
University of Adelaide in 1999, for a thesis entitled 'The effect of cytotoxic chemotherapy on the mucosa of the small intestine'.
Dr Keefe's research interests include mucositis in its broadest sense, covering patho-biology, epidemiology, prevention and treatment.
She has been heavily involved in leading the development of evidence based guidelines for the management of mucositis through MASCC,
as well as co-chairing an international, multi-centre study investigating burden of illness and cost of care for patients with mucositis.
She is also investigating the relationship between mucosal and other toxicities of anti-cancer treatments. Her laboratory work investigates
chemotherapy and radiotherapy-induced whole gut damage, and the efficacy of new agents.
Dr Keefe has authored over 60 peer-reviewed
research publications, the majority on mucositis. She serves on the Editorial Boards of the Asia-Pacific Journal of Clinical Oncology
, and several supportive care journals, including Current Opinions in Supportive and Palliative Care.
C. Kerawala, UK
Mr Cyrus J. Kerawala FDSRCS, FRCS Ed, FRCS (MaxFac)
Consultant Maxillofacial Surgeon at the Royal Surrey County Hospital
(Guildford, UK) and North Hampshire Hospital (Basingstoke, UK)
Cyrus Kerawala graduated with an honours degree in dentistry
from the University of London (The London Hospital) in December 1985. He obtained an FDS from the Royal College of Surgeons of England
in 1990 and graduated with an honours degree in medicine from the University of London (St George's Hospital) in 1992. After experience
in general surgery and neurosurgery he spent five years of specialist training in the North East of England. He passed the Intercollegiate
Examination in Maxillofacial Surgery in September 1998 and has been on the Specialist Register of the General Medical Council since August
1999.
Cyrus Kerawala was appointed as a Consultant in September 1999. His surgical interests concentrate on mucosal and cutaneous
malignancy of the head and neck, particularly reconstruction of the post-ablative defect. In April 2001 he was appointed as Lead Clinician
for Head and Neck Oncology across the Surrey, West Sussex and Hampshire tumour network. His main research areas concern free tissue
transfer, marginal control of disease, management of the neck and the role of chemokine receptor CCR7. Mr. Kerawala devotes a significant
amount of time to teaching, professional training and continuing medical education. He has presented over 80 papers at International
and National meetings.
Academic Distinction and Prizes
1982 Pre-clinical Prize in Anatomy Pre-clinical Prize in Physiology
Pre-clinical Prize in Biochemistry Pre-clinical Prize in Special Dental Anatomy
1985 BDS - Honours in Medicine, Surgery,
Prosthetics and Dental Surgery. George Hankey Prize in Oral Surgery C W F Thomas Prize in Clinical Dental Surgery Harold
Fink Prize in Clinical Dental Surgery
1992 MBBS - Honours in Medicine Brackenbury Prize in Medicine Certificate of Merit
in Psychiatry 1996 The Alexandria Hospital Clinic Prize (British Association of Oral & Maxillofacial Surgeons)
1997 The Norman
Rowe Clinical Prize (British Association of Oral & Maxillofacial Surgeons) The Alexandria Hospital Clinic Prize (British Association
of Oral & Maxillofacial Surgeons)
Current National and International assignments
• Founding Fellow / UK Councillor,
International Academy of Oral Oncology (IAOO) • Chairman, Education and Training Committee, IAOO • Assistant Editor,
International Journal of Oral & Maxillofacial Surgery • Chairman, British Association of Oral & Maxillofacial Surgeons
Information Sub-Committee • Expert Panel Member for Oral Cavity, DAHNO Project • Member of the Intercollegiate Specialties
Board - FRCS (Max-Fac) • Examiner for MFDS and Final FRCS • External Professional Advisor for the Health Service Ombudsman • Member of Appeals Panel for the Postgraduate Medical Education Training Board (PMETB) • Visitor for the Hospital
Recognition Committee of the Royal College of Surgeons of England. • Postgraduate Tutor at the University of Southampton Medical
School • Editorial Advisory Board, British Journal of Oral & Maxillofacial Surgery
C. Leemans, The Netherlands
Prof. Rene Leemans is a graduate of the Erasmus University of Rotterdam School of Medicine in 1985. He received
his residency training in General Surgery at Andreas Hospital and in Otolaryngology at Vrije Universiteit Medical Center (Vumc), both
in Amsterdam. The same University awarded him his PhD in 1992. He was granted a Dutch Cancer Society - fellowship from 1992 to 1994 specialising
further in head and neck oncological and microvascular reconstructive surgery. This training was completed in the departments of Otolaryngology/Head
and Neck Surgery at the VUmc (then headed by prof. dr G.B. Snow), the Netherlands Cancer Institute in Amsterdam, and in the Plastic Surgery
Unit at Canniesburn Hospital in Glasgow (under D.S. Soutar, ChM, FRCS). Hereafter he joined the department of Otolaryngology/Head and
Neck Surgery at the VUmc Amsterdam.
His special interests include head and neck oncology, microvascular surgery, facial plastic surgery,
and basic research.
He is an active member of the Head and Neck Co-operative Group of the EORTC, the American Head and Neck Society,
and the American Academy of Otolaryngology - Head and Neck Surgery. He is a founding member of the European Head and Neck Society, presently
serving as its first Secretary. He (co-)authored around 100 papers and book chapters on head and neck oncology and is regularly invited
to speak at conferences and tutor at courses, both in and outside Europe. He serves on the Editorial Board of several journals.
He
is Director of the Otolaryngology Residency Program and the Advanced Fellowship Program in Head and Neck Surgery and Oncology at the
VU University Medical Centre Amsterdam. He is currently Chief of the Department of Otolaryngology/Head and Neck Surgery, and Professor
of Otolaryngology at the VU University Medical Centre Amsterdam.
L. Lo Muzio, Italy
Prof. Lorenzo Lo Muzio, MD, PhD
Born at Foggia, 12 october 1959 1984 Degree in Medicine, Summa cum laude (University of
Naples, Italy) 1985 Italian certificate of licensure to practice medicine 1987 Postgraduate board in Dentistry, Summa cum laude
(University of Naples, Italy) 1990 Postgraduate board in Oncology, Summa cum laude (University of Naples, Italy) 1996 PhD (SUN
University, Italy) 1997-1998 Postdoctoral felloswship, (University of Naples, Italy) 1998-2000 Professor a.c. at DU of Dental
Igienist at University of Bari 2000-4 Associate professor at Universita Politecnica delle Marche - Ancona. 2004 to date is Associate
Professor at the University of Foggia - Department of Surgical Sciences. 2005 to date is the President of Corso di Laurea in Odontoiatria
e Protesi Dentaria at the University of Foggia. 2005 to date is the President of SIPMO (Society Italian of Oral Pathology and Medicine)
Professor Lo Muzio's research interests cover several fields of oral pathology with a special interest in oral oncogenesis (apoptosis,
cell-cell adhesion.). He received several grants for his research on oral oncology: 1) Chief of the Research Unit for Research Project
"Role of the negative apoptosis regulating proteins in the neoplastic progression of the head and neck carcinomas" coordinated by prof.
Gaetano De Rosa, MURST 2002 - 174.500 Euro; 2) Chief of the Research Unit for the Research Project Compagnia S. Paolo "Impiego clinico
dell'espressione di alcuni marcatori biologici del carcinoma orale come indicatori prognostici e predittivi della trasformazione neoplastica
delle lesioni orali precancerose" with a grant of 100.000 Euro - year 2002; 3) Chief of the Research Project "Molecular markers in
oral squamous cell carcinoma and their possible use in early diagnosis, prognosis and drug therapy." MIUR 2004 - 210.800 Euro; 4)
Chief of the Research Project "Analisi dei cambiamenti genetici e fenotipici associabili alla patogenesi del carcinoma squamoso della
regione testa-collo" grant of FONDAZIONE CASSA DI RISPARMIO di Verona, Vicenza, Belluno e Ancona (180.000 Euro - 2005).
Professor
Lo Muzio is author of more than 400 scientific works, 150 of which are publications in international medical journals. He has delivered
a number of lectures, seminars and round table presentations in many University Departments and Hospitals in Italy and abroad.
Dipartimento
di Scienze Chirurgiche Universita degli Studi di Foggia c/o Ospedali Riuniti Vle Pinto 71100 Foggia - Italy Tel.
39 0881 685809 Fax 39 0881 685809 llomuzio@tin.it or lomuziol@tin.it
E. Maiorano, ItalyProfessor Eugenio Maiorano qualified in Medicine at the University of Bari School of Medicine in 1983 (Summa cum Laude). His post-doctoral
training was at the Post-Graduate Schools of Pathological Anatomy and of Haematology, and he qualified as Specialist in Pathology (1987,
Summa cum Laude) and Haematology (1995, Summa cum Laude) at the University of Bari. He completed a Post-Doctoral Fellowship in Immunopathology
at the Department of Pathology, University of Southern California in Los Angeles (1986) and one in Immunoelectronmicroscopy at the 2nd
Department of Pathology of the University of Milan (1987-88).
He was appointed University Researcher (1990-98) and Associate Professor
of Pathology (from 1998) at the Department of Pathology & Genetics of the University of Bari, where he currently chiefs the Unit
of Head and Neck Pathology and supervises the Section of Immunohistochemistry.
His research interests cover several fields of surgical
pathology with a special interest in head and neck pathology. He has published 122 original research papers, 4 chapters in books and
2 reviews.
Several studies have been focused on the pathogenetic role of Insulin-like growth factor-1 and Transforming growth factor-b.
Recent publications include: - Perlino E, Loverro G, Maiorano E, Giannini T, Cazzolla A, Napoli A, Fiore MG, Ricco R, Marra E,
Selvaggi L: Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma. Br J Cancer 77:1260-6;
1998
- Maiorano E, Ciampolillo A, Gesualdo L, et al.: "Expression of transforming growth factor-b 1 in thyroid tumors". Appl Immunohistochem Molec Morphol7: 135-141; 1999
- Maiorano E, Loverro G, Viale G, Giannini T, Napoli A,
Perlino E: Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer80:188-93; 1999
- Maiorano E, Ciampolillo A, Viale G, et al.: "Insulin-like growth factor-1 expression in thyroid tumours". Appl
Immunohistochem Molec Morphol8: 110-119; 2000
He is also interested in the expression and prognostic relevance of the
epidermal growth factor receptor in oral and laryngeal cancer and pre-cancer, and odontogenic, salivary and other tumors; recent publications
include:
- Maiorano E, Botticella MA, Marzullo A, Resta L: "Expression of ER-D5 and EGFr in laryngeal carcinoma and in pre-malignant
epithelium". Acta Oto-laryngol (Stockh) Suppl 527: 95-99; 1997
- Maiorano E, Favia G, Maissoneuve P, Viale
G: Prognostic implications of Epidermal Growth Factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J
Pathol185: 167-174; 1998
- Maiorano E, Favia GF, Ricco R: "Sialadenoma papilliferum: an immunohistochemical study
of five cases". J Oral Pathol Med25: 336-342; 1996
- Maiorano E, Altini M, Favia G: Clear cell tumours of
the salivary glands, jaws and oral mucosa Semin Diagn Pathol14: 203-212; 1997
- Maiorano E, Favia G, Viale
G: "Lymphoepithelial cysts of salivary glands: an immunohistochemical study of HIV-related and HIV-unrelated lesions". Hum Pathol29: 260-265; 1998
- Altini M, Coleman H, Favia G, Maiorano E: Calretinin expression in ameloblastomas. Histopathology37: 27-32; 2000
- Maiorano E, Favia G, Napoli A, Resta L, Ricco R, Viale G, Altini M: Cellular heterogeneity of granular
cell tumours: a clue to their nature? J Oral Pathol Med29: 284-290; 2000
- Mistry D, Altini M, Coleman HG, Ali H, Maiorano E: The spatial and temporal expression of calretinin in developing rat molars (Rattus norvegicus). Arch Oral Biol46:973-81; 2001
- Coleman H, Altini M, Ali H, Doglioni C, Favia G, Maiorano E: Use of calretinin in the differential
diagnosis of unicystic ameloblastomas. Histopathology 38:312-7; 2001
- Maiorano E, Altini M, Viale G, Piattelli A,
Favia G: Clear cell odontogenic carcinoma. Report of two cases and review of the literature. Am J Clin Pathol116:107-14;
2001
Associate Professor of Osaka University Graduate School of Dentistry (Division of
Oromaxillofacial Regeneration, Department of Prosthodontics and Oral Rehabilitation). Associate Professor of the Center for Advanced
Medical Engineering and Informatics, Osaka University. Visiting Professor of Hokkaido University (Maxillofacial Prosthetics). Visiting
Professor of Osaka Kawasaki Rehabilitation University (Oral and Maxillofacial Rehabilitation).
Research Activities:
1) Current
research topics: (1) Clinical and basic study on the rehabilitation of oral cancer patients and geriatric patients with dysphagia, (2)
Development of the system for evaluating swallowing function, and (3) Cerebral blood flow change during chewing.
2) Member of International
Association for Dental Research and European College of Gerodontology (Councilor). Associate editor of "Gerodontology" and "Journal of
Prosthodontic Research".
3) Certification: Supervisory Prosthodontist, Specialist of Maxillofacial Prosthetics, Specialist of Geriatric
Dentistry
4) Awards: Distinguished Research Paper Award of Japanese Society of Maxillofacial Prosthetics (May 2000, Sept. 2003), Distinguished
Oral Presentation Award of Japanese Society of Prosthodontic Dentistry (Jun 2001), Distinguished Research Paper Award of Japanese Society
of Prosthodontic Dentistry (May 2004), European College of Gerodontology GABA Research Award (Sept. 2006).
Current Publication
in English:
1) Ono, T., Kohda, H., Hori, K., Nokubi, T. (2007): Masticatory performance in post-maxillectomy patients with edentulous
maxilla fitted with obturator prosthesis. International Journal of Prosthodontics, 20: 145-150.
2) Hasegawa, Y., Ono, T., Hori, K.,
Nokubi, T. (2007): Influence of Human Jaw Movement on Cerebral Blood Flow. Journal of Dental Research, 86: 64-68.
3) Yoshida, A.,
Yamamoto, M., Moritani, M., Chang, Z., Taki, I., Tomita, A., Ono, T., Bae, Y-C., Shigenaga, Y. (2007): The somatotopic organization of
trigeminal premotoneurons in the cat brainstem. Brain Research, 1149: 111-117.
4) Ono, T., Kohda, H., Hori, K., Iwata H., Shiroshita,
N., Yamamoto, M., Nokubi, T. (2007): Predictive factors of masticatory performance in post-maxillectomy obturator wearers with soft palate
defect that is either absent or limited to anterior part. Prosthodontic Research and Practice, 6: 181-187.
5) Ono, T., Hasegawa, Y.,
Hori, K., Nokubi, T. (2007): Task-induced activation and hemispheric dominance in cerebral circulation during gum chewing. Journal of
Neurology, 254:1427-1432.
6) Ono, T., Kumakura, I., Arimoto, M., Hori, K., Dong, J., Nokubi, T., Tsuga, K., Akagawa, Y. (2007): Influence
of bite force and tongue pressure on oro-pharyngeal residue in elderly. Gerodontology, 24: 143-150.
7) Ono, T., Hori, K., Tamine,
K., Shiroshita N., Kondoh, J., Maeda, Y. (2008): Application of tongue pressure measurement to rehabilitation of dysphagic patients with
prosthesis. Prosthodontic Research and Practice, 7: 240-242.
8) Zhang, M., Chen, Y-J., Ono, T., Wang J-J. (2008): Crosstalk between
integrin and G protein pathways involved in mechanotransduction in mandibular condylar chondrocytes under pressure. Archives of Biochemistry
and Biophysics, in press.
9) Ono, T., Hori, K., Maeda, Y. (2008): Tongue movement during mastication and swallowing in normal subjects
and dysphasic patients; from observation to quantitative analysis. The Japanese Dental Science Review, in press.
10) Hori, K., Ono,
T., Tamine, K., Iwata H., Kondoh, J., Maeda Y., Dong, J., Hatsuda, M. (2008): A newly developed sensor sheet for measuring tongue pressure
in swallowing. Journal of Prosthodontic Research, in press.
PD Dr. Dirk Rades, MD, PhD, graduated in Medicine from the University of Hamburg in 1991. After his formal
residency in Internal Medicine and Radiology, he started his residency training in Radiation Oncology at Hannover Medical University
in 1997. After his board certification in Radiation Oncology, he became registrar at the Department of Radiation Oncology, University
Medical Center Hamburg-Eppendorf, in 2002. In 2003, he was appointed consultant at the Department of Radiation Oncology, University Medical
Center Hamburg-Eppendorf and completed his habilitation (at least equivalent to PhD), title: "Diagnosis, Prognosis and Radiation Therapy
of Central Nervous System Tumours leading to Motor Deficits". He received his Venia legendi (Associate Professor) for Radiation Oncology
in 2004. In 2005, he was appointed Vice Chair of the Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, and
in 2006 he was appointed Vice Chair of the Department of Radiation Oncology, University Hospital Schleswig-Holstein, Luebeck.
Further
appointments: 2004: Visiting Scientist at the Academic Medical Center Amsterdam, The Netherlands 2005: Expert, consultant,
and lecturer of International Atomic Energy Agency (IAEA) for Radiotherapy of Head and Neck Cancer and for Radiotherapy of Bone Metastases 2006: Member of the Editorial Board of the "International Journal of Radiation Oncology Biology Physics" 2006: Invitation as
Visiting Professor of Radiation Oncology (head and neck cancer, palliative radiotherapy) by the Chiang Mai University, Thailand
Invited
Reviewer for various journals such as: "International Journal of Radiation Oncology Biology Physics" "Radiotherapy &
Oncology" "Strahlentherapie und Onkologie" "Neuropathology and Applied Neurobiology" "Clinical Neurology and Neurosurgery"
"International Journal of Radiation Biology" "Neuro-Oncology" "Nature Clinical Practice Oncology "
Publications
as first author since 2001: 1. Rades D, Baumann R, Bremer M, Leuwer M, Karstens JH. Application of a new verification technique
allowing craniospinal irradiation in supine position. Radiother Oncol 2001;58:215-217. 2. Rades D, Bremer M, Goehde S, Joergensen
M, Karstens JH. Spondylodiscitis in patients with spinal cord compression: a possible pitfall in radiation oncology. Radiother Oncol
2001;59:307-309. 3. Rades D, Heidenreich F, Bremer M, Karstens JH. Time of developing motor deficits before radiotherapy as a new
and relevant prognostic factor in metastatic spinal cord compression: final results of a retrospective analysis. Eur Neurol 2001;45:266-269. 4. Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W. Localised disease in cancer of unknown primary (CUP): the value
of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605-1609. 5. Rades D, Heidenreich
F, Tatagiba M, Brandis A, Karstens JH. Therapeutic options for meningeal melanocytoma and presentation of a rare metastatic case. J Neurosurg
2001;95:225-231. 6. Rades D, Muente S, Baumann R, Karstens JH, Piepenbrock S, Leuwer M. Avoiding endotracheal intubation in children
during craniospinal irradiation. Paediatr Anaesth 2001;11:629-630. 7. Rades D, Kuhnel G, Wildfang I, Borner AR, Knapp W, Karstens
JH. The value of Positron-Emission-Tomography (PET) for the therapeutic management in patients with cancer of unknown primary (CUP).
Strahlenther Onkol 2001;177:525-529. 8. Rades D, Tatagiba M, Brandis A, Dubben HH, Karstens JH. The value of radiotherapy for the
treatment of meningeal melanocytoma. Strahlenther Onkol 2002;178:336-342. 9. Rades D, Heidenreich F, Karstens JH. Final results of
a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression.
Int J Radiat Oncol Biol Phys 2002;53:975-979. 10. Rades D, Karstens JH. A comparison of two different radiation schedules for metastatic
spinal cord compression considering a new prognostic factor. Strahlenther Onkol 2002;178:556-561. 11. Rades D, Fehlauer F. Treatment
options for central neurocytoma. Neurology 2002;59:1268-1270. 12. Rades D, Karstens JH, Alberti W. The role of radiotherapy in the
treatment of motor dysfunction due to metastatic spinal cord compression: a comparison of three different fractionation schedules. Int
J Radiat Oncol Biol Phys 2002;54:1160-1164. 13. Rades D, Bajrovic A, Alberti W, Rudat V. Is there a dose effect relationship for
the treatment of symptomatic vertebral hemangioma? Int J Radiat Oncol Biol Phys 2003;55:178-181. 14. Rades D, Schild SE, Ikezaki
K, Fehlauer F. Defining the optimal dose of radiation after incomplete resection of central neurocytomas. Int J Radiat Oncol Biol Phys
2003;55:373-377. 15. Rades D, Fehlauer F, Schild SE, Lamszus K, Alberti W. Treatment for central neurocytoma: a metaanalysis based
on the data of 358 patients. Strahlenther Onkol 2003;179:213-218. 16. Rades D, Fehlauer F, Schild SE. Treatment of atypical neurocytomas.
Cancer 2004;100:814-817. 17. Rades D, Raabe A, Bajrovic A, Alberti W. Treatment of solitary brain metastasis: resection followed
by whole brain radiation therapy (WBRT) and a radiation boost to the metastatic site. Strahlenther Onkol 2004;180:144-147. 18. Rades
D, Schild SE, Fehlauer F. The prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology 2004;62:987-989. 19.
Rades D, Fehlauer F, Hartmann A, Wildfang I, Karstens JH, Alberti W. Reducing the overall treatment time for radiotherapy of metastatic
spinal cord compression (MSCC): 3-year results of a prospective observational multi-center study. J Neuro-Oncol 2004;70:77-82. 20.
Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head
and neck cancer patients. Radiother Oncol 2004;70:261-264. 21. Rades D, Schild SE, Tatagiba M, Molina HA, Alberti W. Therapy of meningeal
melanocytomas. Cancer 2004;100:2442-2447. 22. Rades D. Reply to the letter by M. Cengiz et al. Radiother Oncol 2004;73:109-110. 23.
Rades D, Schild SE, Fehlauer F. Defining the best available treatment for neurocytomas in children. Cancer 2004;101:2629-2632. 24.
Rades D, Fehlauer F, Stalpers LJA, Wildfang I, Zschenker O, Schild SE, Schmoll HJ, Karstens JH, Alberti W. A prospective evaluation of
two radiation schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multi-center
study. Cancer 2004;101:2687-2692. 25. Rades D, Fehlauer F, Ikezaki K, Schild SE. Dose-effect relationship for radiotherapy after
incomplete resection of atypical neurocytomas. Radiother Oncol 2005;74:67-69. 26. Rades D, Fehlauer F, Lamszus K, Schild SE, Hagel
C, Westphal M, Alberti W. Well differentiated neurocytoma: What is the best available treatment? Neuro-Oncol 2005;7:77-83. 27. Rades
D, Stalpers LJA, Hulshof MC, Zschenker O, Alberti W, Koning CCE. Effectiveness and toxicity of single-fraction radiotherapy with 1x8
Gy for metastatic spinal cord compression. Radiother Oncol 2005;75:70-73. 28. Rades D, Schild SE, Bahrehmand R, Zschenker O, Alberti
W, Rudat V. Prognostic Factors in the Non-Surgical Treatment of Esophageal Cancer with Radiotherapy or Radiochemotherapy: The Importance
of Pre-treatment Hemoglobin Levels. Cancer 2005;103:1740-1746. 29. Rades D, Stalpers LJA, Hulshof MC, Borgmann K, Karstens JH, Koning
CCE, Alberti W. Comparison of 1x8 Gy and 10x3 Gy for functional outcome in patients with metastatic spinal cord compression. Int J Radiat
Oncol Biol Phys 2005;62:514-518. 30. Rades D, Schild SE, Yekebas EF, Job H, Schwarz R, Rudat V. Epoetin-alpha during radiotherapy
for stage III esophageal carcinoma. Cancer 2005;103:2274-2279. 31. Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic
N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of five radiation schedules and prognostic factors
for metastatic spinal cord compression. J Clin Oncol 2005;23:3366-3375. 32. Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ,
Alberti W. Effektivit?t und Toxizit?t einer Re-Bestrahlung (Re-RT) bei metastatisch bedingter R?ckenmarkskompression (MBRK). Strahlenther
Onkol 2005;181:595-600. 33. Rades D, Stalpers LJ, Veninga T, Hoskin PJ. Spinal reirradiation after short-course RT for metastatic
spinal cord compression. Int J Radiat Oncol Biol Phys 2005;63:872-875. 34. Rades D, Veninga T, Stalpers LJ, Schulte R, Hoskin PJ,
Poortmans P, Schild SE, Rudat V. Prognostic factors predicting functional outcome, recurrence-free survival, and overall survival after
radiotherapy of metastatic spinal cord compression in breast cancer patients. Int J Radiat Oncol Biol Phys 2006;64:182-188. 35. Rades
D, Stalpers LJ, Veninga T, Rudat V, Schulte R, Hoskin PJ. Evaluation of functional outcome and local control after radiotherapy for metastatic
spinal cord compression in prostate cancer patients. J Urol 2006;175:552-556. 36. Rades D, Schild SE. The value of post-operative
stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas. Cancer 2006;106:1140-1143. 37.
Rades D, Hoskin PJ, Stalpers LJA, Schulte R, Poortmans P, Veninga T, Dahm-Daphi J, Obralic N, Wildfang I, Bahrehmand R, Engenhart-Cabilic
R, Schild SE. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006;64:1452-1457. 38. Rades D, Walz J, Stalpers LJA, Veninga T, Schulte R, Obralic N, Wildfang I, Engenhart-Cabilic R, Hoskin PJ, Schild SE. Short-course
radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center
study. Eur Urol 2006;49:846-852. 39. Rades D, Lang S, Schild SE, Alberti W. Prognostic value of the hemoglobin levels during concurrent
radio-chemotherapy in the treatment of esophageal cancer. Clin Oncol 2006;18:139-144. 40. Rades D, Schild SE. Treatment recommendations
for the various subgroups of neurocytomas. J Neuro-Oncol 2006; 77:305-309. 41. Rades D, Schild SE. Dose-response relationship for
fractionated irradiation in the treatment of spinal meningeal melanocytomas: a review of the literature. J Neuro-Oncol 2006; 77:311-314. 42. Rades D, Stalpers LJA, Schulte R, Veninga T, Basic H, Engenhart-Cabillic R, Schild SE, Hoskin PJ. Defining the appropriate radiotherapy
regimen for metastatic spinal cord compression (MSCC) in non-small cell lung cancer (NSCLC) patients. Eur J Cancer 2006; 42:1052-1056. 43. Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I, Kilic E, Muellerleile U, Gross E, Schild SE, Alberti W. Epoetin alfa
improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat
Oncol Biol Phys 2006; 65:459-465. 44. Rades D, Schild SE. Is 50 Gy sufficient to achieve long-term local control after incomplete
resection of typical neurocytomas? Strahlenther Onkol 2006;182:415-418. 45. Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ,
Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabillic R, Karstens JH, Alberti W, Dunst J, Schild SE. Prognostic
factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 2006; 24:3388-3393.
A. Rapidis, GreeceConsultant and Head, Department of Maxillofacial Surgery, Greek Anticancer Institute, Saint Savvas Hospital, Athens
Assistant Professor
in Maxillofacial Surgery, University of Athens, Athens, Greece, Hon. Senior Lecturer in Maxillofacial Surgery, Eastman Dental Institute,
University College London, England
Alexander D. Rapidis graduated in Dentistry and Medicine from the University of Athens and holds
a PhD degree in Oral Medicine and Pathology. He was trained in Oral and Maxillofacial Surgery at the University of London and was a Hon.
Lecturer in Oral and Maxillofacial Surgery in King's College Hospital Medical School. After his return to Greece, he was a Senior Registrar
in Maxillofacial Surgery in the Athens Accident Hospital and the Laiko General University Hospital. Since 1990 he is Consultant and Head
of the Department of Maxillofacial Surgery of the Greek Anticancer Institute "Saint Savvas Hospital" in Athens. In 2000 he was elected
Assistant Professor of Oral and Maxillofacial Surgery in the University of Athens and in 2004 Hon. Senior Lecturer in Maxillofacial Surgery
at Eastman Dental Institute, University College London, England.
Dr Rapidis is a Fellow of the European Boards of Oro-Maxillofacial
Surgery UMS, member of the National Council of Research and Technology of the Greek Ministry of Development, Chairman of the Surgical
Division of Saint Savvas Hospital and member of the Greek Examining Boards for the specialty of Oral and Maxillofacial Surgery. During
the last five years he founded along with the Department of Plastic and Reconstructive Surgery the first unit of reconstructive microsurgery
of the maxillofacial region.
He is the author of more than 400 scientific works, 180 of which are publications in national and international
medical journals. He has delivered a number of lectures, seminars and round table presentations in many University Departments and Hospitals
in Greece and abroad.
S. Rogers, UK
Simon Rogers BDS MBChB (Hons) FSD RCS (Eng), FRCS (Eng) FRCS (Max) MD
Simon qualified from Sheffield University Dental School
in the Christmas of 1984. He became a Fellow of the Dental Faculty of the Royal College of Surgeons England in 1988 and qualified with
honours from Birmingham University Medical School in 1990. In 1994 he passed his general surgical fellowship from the Royal College
of Surgeons England and in 1997 won the gold medal in the Intercollegiate Oral and Maxillofacial examination. In January 1999 Simon
was appointed Consultant Maxillofacial Surgeon at the University Hospital Aintree and Honorary Reader, University of Liverpool. He is
part of the multidisciplinary head and neck team and specialises in oral and oropharyngeal cancer and microvascular free tissue reconstruction.
He believes with passion in the qualities reflected in Practice Development Unit (PDU) with emphasis on evidence based practice, questioning
culture, patient focus, holistic care, multi-speciality collaboration and team working. He has an interest in health related quality
of life following oral cancer and in 2000 was awarded a higher degree from the University of Birmingham. In 2002 he was awarded a Hunterian
Professorship from the Royal College of Surgeons of England for his research into the relationship between function and quality of life
following primary surgery for oral and oropharyngeal cancer. He has several ongoing HRQOL studies, has published widely on this topic,
and has been invited to speaker at many national and international scientific meetings. He has organised four International HRQOL workshops
hosted at Liverpool and the next is scheduled for October 2006. He has recently demitted office as Chairman of the BAOMS Clinical Effectiveness
Sub-committee and has taken on the role as Clinical Director of the Regional Maxillofacial Unit. This year he was awarded the prestigious
BAOMS Surgery Prize in recognition of the contribution he has made to the speciality. He was an invited founder fellow of the International
Academy of Oral Oncology.
M. Rosin, Canada
Dr. Miriam P. Rosin received her Ph.D. in cell biology from the University of Toronto in 1976 and began her cancer
research career with a post-doctoral position with Dr. Hans Stich's Environmental Carcinogensis Unit at the British Columbia Cancer Agency
(BCCA) Research Centre. It was during that time she began extensive research in modeling human cancers, working to develop markers that
would detect the disease at premalignant stages, to better understand the natural history of the disease. She became a staff scientist
at BCCA in 1978 and her research quickly took her to the high altitude houses on stilts in the Philippines mountains, the collective
farms of Uzbekistan in the former Soviet Union, and lively and exotic fishing villages in southern India. This translational research
in high-risk populations in India, the Philippines, Taiwan, Guam and the old Russia, involving the assessment of oral lesions in tobacco-chewing
populations at high risk for oral cancer development, became the basis for Dr. Rosin's later work. These studies were among the first
nationally and internationally to use oral mucosa brushings for studies on noninvasive biomarkers of risk before and after intervention
with chemopreventive agents. More recently, a parallel approach has been developed in Vancouver to demonstrate the ability to detect
clones of cells with abnormal molecular patterns in oral premalignant lesions in cells scraped from the oral surface of such lesions.
Dr. Rosin became an Associate Professor at Simon Fraser University in 1987 when she founded the Cancer Prevention Laboratory there,
rising to Full Professor in 1992, but remaining a senior scientist at B.C. Cancer and a Clinical Full Professor (as of 1993) at the University
of British Columbia, Pathology and Laboratory Science. During this time, she formed a coalition with Egyptian scientists to study Schistomosa
haematobium, looking at associations between chronic infection with this parasite, inflammation and bladder cancer. She also began to
establish associations with fellow scientists in British Columbia and the United States that eventually would lead to what has become
her most recognized, and most cherished, work.
After a year's sabbatical spent studying with Dr. David Sidransky at the Department
of Otolaryngology at Johns Hopkins University, she embarked on an ambitious and far-reaching program aimed at producing a system-wide
change in the process of oral cancer/precancer detection, risk assessment and management in British Columbia. In 2003, she added the
title of Director of the BC Oral Cancer Prevention Program (BC OCPP) and Oral Health Research Network to her other titles. The Program
has grown to include more than 30 team members, working in multiple disciplines with support from numerous agencies: NIH, CIHR, NSERC,
Genome BC/Canada, Michael Smith Foundation, BC Cancer Foundation. It now links community health professionals in a step-wise referral
pathway using a risk assessment approach to ensure seamless management of the disease from early dysplasia to frank malignancy. To facilitate
change, the program has developed and is evaluating new technology that utilizes multiple systems for assessment - optical devices to
improve clinical visualization; high throughput computer microscopy systems to predict future behavior of early lesions in a cost effective
fashion, using subtle histological and cytological indicators; and molecular markers of risk. These technologies are now in place in
the referral pathway and are beginning to be used to remove barriers to patient flow. The BC OCPP is currently involved in integrating
community structures throughout the province to move this endeavour to a population-wide initiative, by engaging dental networks for
screening (guidelines issued in March 2008 along with protocols) and through community partnership in hard-to-reach communities. A description
of the program is given at www.orcanet.ca.
Dr. Rosin has published over 120 publications, is a frequent invited speaker
at national and international meetings and has served on panels and working groups with numerous agencies including NIH, IARC, WHO, NCI
and CIHR.
Professor Kanemitsu Shirasuna qualified in Dentistry at Osaka Dental College in 1970. He worked as a Resident
(1970-1973), Assistant Professor (1974-1986), and Associate Professor (1987-1995) in the lst Department of Oral and Maxillofacial Surgery,
in the Faculty of Dentistry, at Osaka University. He was awarded a Doctor of Philosophy in Dental Science by Osaka University in 1977,
and was certified by the Specialty Board in Oral and Maxillofacial Surgery in 1986. In 1995, he was appointed Chairman and Professor
of the Department of Oral and Maxillofacial Surgery, at the Graduate School of Dental Science, Kyushu University.
Dr. Shirasuna is
a member of the American Association of Cancer Research, the International Association of Oral and Maxillofacial Surgeons, the Japanese
Society of Oral and Maxillofacial Surgeons, the Japanese Cancer Association, the Japan Society of Clinical Oncology, the Japan Society
for Head and Neck Cancer, and the Japanese Stomatological Society.
Dr. Shirasuna's main research has been in tumor biology, especially
the biological characterization of salivary gland tumors and the mechanism of invasion of oral cancer. His group has established and
characterized several neoplastic cell lines from human salivary glands, and their works have been published in a variety of journals.
Among these cell lines, an HSG cell line showing the phenotype of intercalated duct cells, which was established from a human submandibular
gland (Shirasuna et al., Cancer (Phila.), 1081), has been used widely for studying the growth and differentiation mechanism of salivary
gland epithelial cells (Shirasuna et al., BBRC, 1986; Cancer Res., 1986; 1988).
Dr. Shirasuna works mainly on adenoid cystic carcinoma
(AdCC) and has shown that cell lines derived from human AdCC display the potential to produce a large amount of ECM, including basement
membrane proteins, and form pseudocysts, a specific architectural feature of AdCC (Shirasuna et al., Cancer Res., 1990). AdCC cell lines
also produce significant amounts of proteases, including urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs),
and can degrade considerable amounts of ECM elaborated by normal mesenchymal cells, mainly via the uPA-plasmin cascade. However, the
ECM elaborated by AdCC cells is resistant to degradation by the tumor cells because of high levels of plasminogen activator inhibitor
type 1 (PAP 1) in the ECM (Shirasuna et al., Cancer Res., 1993).
Dr. Shirasuna and his coworkers are studying the interaction of proteases
and adhesion molecules in oral squamous cell carcinoma (SCC) and salivary gland tumor cells to elucidate the mechanism regulating cancer
invasion and metastasis.
He has demonstrated adhesion molecules (Sugiura et al., Int. J, Cancer, 1996; Shinoliara et al., J. Pathol.,
1998; Am. J. Clin, Pathol., 1998), and increased expression of a variety of proteases in oral SCC (Kurahara et al., Head & Neck,
1999; Ikebe et al., Clinical. Experimental Metastasis, 1999). His group has also demonstrated that epidermal growth factor (EGF) and
turnor necrosis factor-ot jNF-ot) stimulate uPA and MMP-9 production and factors related to angiogenesis, through transcription factors,
such as AP- 1, NF KB, and Sp 1. His group have also reported that TNF-ct-induced migration of oral SCC cells is blocked by a specific
proteasome inhibitor, lactacystin, through inhibition of NF-KB activation and NIMP-9 production (Ikebe et al., Int. J. Cancer, 1998).
They also found that dexamethasone inhibits growth-factor-induced invasion of SCC cells by increasing expression of PAI-1 and decreasing
expression of uPA, uPA receptors, and MNIP-9 (Hayashido et al., Cancer Lett., 1996). More recently, his group have demonstrated that
transfection of oligodeoxynucleotides containing the consensus sequence for Sp I binding would be an effective way of regulating tumor
growth by reducing cancer cell angiogenic growth factor expression and invasiveness (Ishibashi et al., Cancer Res., 2000).
T. Teknos, USA
Theodoros N. Teknos, MD
Dr. Ted Teknos graduated from Harvard Medical School in 1991. He completed his
Otolaryngology-Head and Neck Surgery residency training at Massachusetts Eye and Ear Infirmary/Harvard in 1996 and a Head and Neck/Microvascular
Reconstructive Surgery fellowship at Vanderbilt University Medical Center in 1997. He subsequently joined the Otolaryngology faculty
at the University of Michigan Health System where he currently the Chief of the Division of Head and Neck Surgery, the Associate Director
of the Microvascular Reconstructive Surgery Program and the Co-Residency Director.
Dr. Teknos also directs an active research laboratory
investigating the molecular basis of antiangiogenic therapy in head and neck cancer. He is a fellow of the American Academy of Otolaryngology,
the American College of Surgeons, the American Head and Neck Society, the American Association for Cancer Research and a founding fellow
of the International Association of Oral Oncology.
T. Whiteside, USA
Dr. Theresa L. Whiteside, Ph. D. Professor of Pathology, Immunology and Otolaryngology Director
of the Immunologic Monitoring and Cellular Products Laboratory University of Pittsburgh Cancer Institute Phone: 412-624-0096 Email: whitesidetl@msx.upmc.edu
Research Interest: Cancer Therapy, Cellular Therapy, Cell Culture, Immunoassays
Dr.
Whiteside's laboratory studies immunobiology and immunotherapy of human cancer, specifically, of oral carcinoma. As a part of a broadly-designed
research program in human head and neck cancer (HNC), we are studying immune markers (mainly those present on T, NK and DC) to evaluate
their prognostic significance. The role of immune effector cells and their subsets in tumor progression is evaluated. We study ex vivo
immunogenicity of tumor-derived epitopes presented on DC to immune cells and attempt to define the usefulness of these epitopes for vaccines.
We also develop methods for quantitation of the frequency of vaccine-specific or tumor-specific T lymphocytes. One of the unique aspects
of the program is the expertise we have developed in the evaluation of factors that contribute to poor immune responses and apoptosis
of immune cells at the tumor site as well as in the peripheral circulation of patients with cancer. Signaling molecules associated with
TcR in T cells and FcgRIII in NK cells, such as the z chain, are being studied as possible biomarkers of decreased lymphocyte function
in cancer. Multicolor flow cytometry incorporating markers of apoptosis is being adapted to measure the proportions of T cells undergoing
apoptosis at the tumor site and in the circulation of patients with cancer before and after immunotherapy. Tetramer technology is used
extensively to detect and follow the fate of tumor antigen-specific CD8+ cells in patients with cancer. The mechanisms responsible for
lymphocyte apoptosis, including the contribution of the TNF family of receptors and ligands to apoptosis of selected lymphocyte subsets
in these patients are also being assessed. Effects of cytokines on T-cell apoptosis is evaluated, and the cytokines best able to decrease
or prevent spontaneous apoptosis of effector cells are especially targeted. Finally, expression and function of apoptosis inhibitory
molecules such as FLIP and FAP-1 in tumor cells are evaluated in order to be able to decrease and eventually to abolish resistance of
tumor cells to apoptosis mediated by immune cells or other apoptosis-inducing therapies. The major emphasis has been on the generation
of effective cellular immune responses in patients with cancer and on protection of immune cells from tumor-induced death by the use
of exogenous cytokines and other immunomodulatory agents. At the same time, we are purifying and characterizing immunogenic epitopes
from human SCCHN in hope of using them as components of anti-tumor vaccines in the future.
References:
1. Whiteside
TL, Gambotto A, Albers A, Stanson J, Cohen EP. Human Tumor-Derived Genomic DNA Transduced into a Recipient Cell Induces Tumor-Specific
Immune Responses Ex Vivo. PNAS, 99: 9415-9420, 2002.
2. Hoffman TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann
F, Myers EN, Appella E, DeLeo AB, Whiteside TL. Frequencies of Tetramer+ T cells Specific for the Wild-Type Sequence p53264-272
Peptide in the Circulations of Patients with Head and Neck Cancer. Cancer Res., 62: 3521-3529, 2002.
3. Meidenbauer N, Gooding
W, Spliter L, Harris D, Whiteside TL. Recovery of Chain Expression and Changes in Spontaneous IL-10 Production after PSA-Based
Vaccines in Patients with Prostate Cancer. Br. J. Cancer, 86: 168-178, 2002.
4. Whiteside TL, Tumor-Induced Death
of Immune Cells: its Mechanisms and Consequences. Sem. Cancer Biol., 12: 43-50, 2002.
5. Reichert TE, Scheuer C, Day R, Wagner
W, Whiteside TL. The Number of Intratumoral Dendritic cells and -Chain Expression in T Cells as Prognostic and Survival Biomarkers
in Patients with Oral Carcinoma. Cancer, 91: 2136-2147, 2000.
J. Woolgar, UK
Dr Julia Woolgar FRCPath, FDS RCS (Eng), PhD
Dr Julia Woolgar, FRCPath, FDS RCS Eng, PhD, has been Senior Lecturer / Honorary
Consultant in Oral Pathology at the University of Liverpool since 1994. She is the author of over 70 articles, with the majority of recent
ones concerning oral cancer. She co-authors the Royal College of Pathologist's Standard an. Minimum Dataset for Histopathology Reports
on Head and Neck Carcinomas and Salivary Neoplasms (1998, with new edition in press).
Histopathological studies on the local and regional
lymphatic spread of oral cancer and their prognostic importance earned her The International Association of Oral & Maxillofacial
Surgeons Prize for The Best Published Article in the Year 1997 and the Royal College of Surgeons of England John Tomes Prize Medal in
2002.
In addition to her research achievements, she was Chairperson of the Pathology Sub-committee of the Head & Neck Group of
the European Organization for Research and Treatment of Cancer (EORTC) from 2000-2003. Since 1996, she has played a key role in the development
of Quality Assurance Schemes for histopathologists and has been the Organiser of the UK National Head and Neck Histopathology External
Quality Assurance Scheme since its introduction in 2000. Her Editorial Board experience includes Oral Oncology (2001-2), The Asian Journal
of Oral and Maxillofacial Surgery (since 2001), The International Journal of Oral and Maxillofacial Surgery (since 2002) and The British
Journal of Oral and Maxillofacial Surgery (since 2003).
W. Yeudall, USADr. Andrew Yeudall graduated with Honors in Biochemistry from the University of Glasgow, Scotland, in 1983. Subsequently, he obtained
his dental degree from the same university, and worked in junior positions in Oral Surgery and Oral Medicine based in Glasgow Dental
Hospital and School. In 1987, he was awarded a Research Training Fellowship from the Medical Research Council, which enabled him to undertake
a three-year position at the CRC Beatson Institute for Cancer Research in the laboratory of Dr. Saveria Campo, studying the role of human
papillomaviruses in oral squamous carcinogenesis. This research led to the degree of Ph.D., awarded in 1991. Dr. Yeudall was appointed
to a Lectureship in Oral Medicine and Oral Surgery in the University of Bristol, which he held between 1990 and 1993. In 1993, he relocated
to the National Institute of Dental Research as a Visiting Associate in the Laboratory of Cellular Development and Oncology under the
leadership of Dr. Keith Robbins. In this setting, he developed his interests in cell cycle deregulation in head and neck carcinogenesis,
and in the use of cell cycle regulators as molecular therapeutics. During his time at the NIH, Dr. Yeudall was awarded an Honorary Lectureship
in Oral Medicine at the Eastman Dental Institute, University College London, which he held until 1998. In 1999, he was appointed as a
Senior Clinical Investigator in King's College London, based in the Department of Craniofacial Development. In 2001, he was appointed
as a Senior Lecturer in the Departments of Oral Surgery and Craniofacial Development. He currently leads a research group whose efforts
focus on aspects of growth factor receptor signaling pathways and their deregulation in cancer, and modulation of the biological response
of tumor cells to chemo- and radiotherapeutics. He has been an Associate Member of the Cancer Biology and Therapy interdisciplinary research
group at King's College London since 1999. He is a member of the British Association for Cancer Research, the Society for General Microbiology,
and the American Society for Microbiology. His funding sources include the Arthritis Research Campaign, and the Concern Foundation. He
has a number of collaborative studies with researchers both in the UK and USA.
Dr. Yeudall has published more than 40 journal articles,
reviews and book chapters. He is on the Editorial Review Board of Oral Oncology, and reviews submissions for a number of other publications
and funding bodies, including Oral Diseases, Journal of Oral Pathology and Medicine, International Journal of Cancer, Cell Growth and
Differentiation, Invasion and Metastasis, British Journal of Cancer, Arteriosclerosis Thrombosis and Vascular Biology, Oncogene, the
Arthritis Research Campaign, and the Advanced Technology Program of the US Dept. of Commerce. .
Y. Yura, Japan
Business address: Oral and Maxillofacial Surgery II Osaka University Graduate School of Dentistry 1-8 Yamadaoka Suita, Osaka 565-0871 Japan Telephone: +81-6-6879-2941 Facsimile: +81-6- 6879-2170 E-mail: yura@dent.osaka-u.ac.jp
Employment: 1980- 1985 - Assistant Professor, Tokushima University School of Dentistry, Tokushima,
Japan 1985 - 1987 - Senior Assistant Professor, Tokushima University School of Dentistry, Tokushima, Japan 1987-
1989 - Visiting Scholar, Department of Pathology, Northwestern University, Chicago, Illinois, U.S.A. 1989 - 2000 - Senior Assistant
Professor, Tokushima University School of Dentistry, Tokushima, Japan 2000-present - Professor and Chairman, Department of Oral and
Maxillofacial Surgery II, Osaka University Graduate School of Dentistry
Research theme: Gene therapy, Oncolytic virotherapy
for oral cancer with herpes simplex virus Cancer chemotherapy, Protein kinase C and histone deacetylase as molecular targets for
cancer therapy Boron neutron capture therapy, A selective radiotherapy using boron compound and reactor Oral lichen planus and
contact dermatitis, Immunohistological study for oral lichen planus and experimental study for contact dermatitis and mucositis Tissue
engineering, Organic-inorganic composite as a grafting material for bone regeneration
Memberships: Oral Oncology, Editorial
Board Japanese Society of Oral and Maxillofacial Surgeons, Councilor and Director Japanese Stomatological Society, Councilor,
Editorial Board Japanese Society for Oral Mucous Membrane, Councilor and Director Japan Tissue Culture Society for Dental Research,
Councilor and Director Japanese Cancer Association, Member Japanese Society of Clinical Oncology, Member Japan Society
for Head and Neck Cancer, Councilor Japan Society for Oral Tumors, Member America Association for Cancer Research, Member American
Society for Microbiology, Member
Professor Crispian Scully CBE, MD, PhD, MDS, MRCS, BSc, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA,
FUCL, DSc, DChD, DMed(HC) 
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company